1,313 results on '"Hansel, Nadia N."'
Search Results
2. Multi-omics in nasal epithelium reveals three axes of dysregulation for asthma risk in the African Diaspora populations
- Author
-
Szczesny, Brooke, Boorgula, Meher Preethi, Chavan, Sameer, Campbell, Monica, Johnson, Randi K., Kammers, Kai, Thompson, Emma E., Cox, Madison S., Shankar, Gautam, Cox, Corey, Morin, Andréanne, Lorizio, Wendy, Daya, Michelle, Kelada, Samir N. P., Beaty, Terri H., Doumatey, Ayo P., Cruz, Alvaro A., Watson, Harold, Naureckas, Edward T., Giles, B. Louise, Arinola, Ganiyu A., Sogaolu, Olumide, Falade, Adegoke G., Hansel, Nadia N., Yang, Ivana V., Olopade, Christopher O., Rotimi, Charles N., Landis, R. Clive, Figueiredo, Camila A., Altman, Matthew C., Kenny, Eimear, Ruczinski, Ingo, Liu, Andrew H., Ober, Carole, Taub, Margaret A., Barnes, Kathleen C., and Mathias, Rasika A.
- Published
- 2024
- Full Text
- View/download PDF
3. Bronchodilator Responsiveness in Tobacco-Exposed People With or Without COPD
- Author
-
Fortis, Spyridon, Quibrera, Pedro M, Comellas, Alejandro P, Bhatt, Surya P, Tashkin, Donald P, Hoffman, Eric A, Criner, Gerard J, Han, MeiLan K, Barr, R Graham, Arjomandi, Mehrdad, Dransfield, Mark B, Peters, Stephen P, Dolezal, Brett A, Kim, Victor, Putcha, Nirupama, Rennard, Stephen I, Paine, Robert, Kanner, Richard E, Curtis, Jeffrey L, Bowler, Russell P, Martinez, Fernando J, Hansel, Nadia N, Krishnan, Jerry A, Woodruff, Prescott G, Barjaktarevic, Igor Z, Couper, David, Anderson, Wayne H, Cooper, Christopher B, Investigators, Subpopulations and Intermediate Outcome Measures in COPD Study, Alexis, Neil E, Barjaktarevic, Igor, Basta, Patricia, Bateman, Lori A, Bleecker, Eugene R, Boucher, Richard C, Christenson, Stephanie A, Couper, David J, Crystal, Ronald G, Doerschuk, Claire M, Dransfield, Mark T, Drummond, Brad, Freeman, Christine M, Galban, Craig, Hastie, Annette T, Huang, Yvonne, Kaner, Robert J, Kleerup, Eric C, LaVange, Lisa M, Lazarus, Stephen C, Meyers, Deborah A, Moore, Wendy C, Newell, John D, Paulin, Laura, Pirozzi, Cheryl, Oelsner, Elizabeth C, O’Neal, Wanda K, Ortega, Victor E, Raman, Sanjeev, Wells, J Michael, and Wise, Robert A
- Subjects
Biomedical and Clinical Sciences ,Cardiovascular Medicine and Haematology ,Clinical Sciences ,Clinical Research ,Lung ,Chronic Obstructive Pulmonary Disease ,Respiratory ,Good Health and Well Being ,Humans ,Bronchodilator Agents ,Nicotiana ,Retrospective Studies ,Forced Expiratory Volume ,Pulmonary Disease ,Chronic Obstructive ,Asthma ,Vital Capacity ,bronchodilator ,bronchodilator response ,bronchodilator responsiveness ,bronchodilator reversibility ,COPD ,Subpopulations and Intermediate Outcome Measures in COPD Study Investigators ,Respiratory System ,Cardiovascular medicine and haematology ,Clinical sciences - Abstract
BackgroundBronchodilator responsiveness (BDR) in obstructive lung disease varies over time and may be associated with distinct clinical features.Research questionIs consistent BDR over time (always present) differentially associated with obstructive lung disease features relative to inconsistent (sometimes present) or never (never present) BDR in tobacco-exposed people with or without COPD?Study design and methodsWe retrospectively analyzed data from 2,269 tobacco-exposed participants in the Subpopulations and Intermediate Outcome Measures in COPD Study with or without COPD. We used various BDR definitions: change of ≥ 200 mL and ≥ 12% in FEV1 (FEV1-BDR), change in FVC (FVC-BDR), and change in in FEV1, FVC or both (ATS-BDR). Using generalized linear models adjusted for demographics, smoking history, FEV1 % predicted after bronchodilator administration, and number of visits that the participant completed, we assessed the association of BDR group: (1) consistent BDR, (2) inconsistent BDR, and (3) never BDR with asthma, CT scan features, blood eosinophil levels, and FEV1 decline in participants without COPD (Global Initiative for Chronic Obstructive Lung Disease [GOLD] stage 0) and the entire cohort (participants with or without COPD).ResultsBoth consistent and inconsistent ATS-BDR were associated with asthma history and greater small airways disease (%parametric response mapping functional small airways disease) relative to never ATS-BDR in participants with GOLD stage 0 disease and the entire cohort. We observed similar findings using FEV1-BDR and FVC-BDR definitions. Eosinophils did not vary consistently among BDR groups. Consistent BDR was associated with FEV1 decline over time relative to never BDR in the entire cohort. In participants with GOLD stage 0 disease, both the inconsistent ATS-BDR group (OR, 3.20; 95% CI, 2.21-4.66; P < .001) and consistent ATS-BDR group (OR, 9.48; 95% CI, 3.77-29.12; P < .001) were associated with progression to COPD relative to the never ATS-BDR group.InterpretationDemonstration of BDR, even once, describes an obstructive lung disease phenotype with a history of asthma and greater small airways disease. Consistent demonstration of BDR indicated a high risk of lung function decline over time in the entire cohort and was associated with higher risk of progression to COPD in patients with GOLD stage 0 disease.
- Published
- 2023
4. Use of the Spirometric “Fixed-Ratio” Underdiagnoses COPD in African-Americans in a Longitudinal Cohort Study
- Author
-
Regan, Elizabeth A., Lowe, Melissa E., Make, Barry J., Curtis, Jeffrey L., Chen, Quan (Grace), Cho, Michael H., Crooks, James L., Lowe, Katherine E., Wilson, Carla, O’Brien, James K., Oates, Gabriela R., Baldomero, Arianne K., Kinney, Gregory L., Young, Kendra A., Diaz, Alejandro A., Bhatt, Surya P., McCormack, Meredith C., Hansel, Nadia N., Kim, Victor, Richmond, Nicole E., Westney, Gloria E., Foreman, Marilyn G., Conrad, Douglas J., DeMeo, Dawn L., Hoth, Karin F., Amaza, Hannatu, Balasubramanian, Aparna, Kallet, Julia, Watts, Shandi, Hanania, Nicola A., Hokanson, John, Beaty, Terri H., Crapo, James D., Silverman, Edwin K., Casaburi, Richard, and Wise, Robert
- Published
- 2023
- Full Text
- View/download PDF
5. Bronchodilators in Tobacco-Exposed Persons with Symptoms and Preserved Lung Function
- Author
-
Han, MeiLan K, Ye, Wen, Wang, Di, White, Emily, Arjomandi, Mehrdad, Barjaktarevic, Igor Z, Brown, Stacey-Ann, Buhr, Russell G, Comellas, Alejandro P, Cooper, Christopher B, Criner, Gerard J, Dransfield, Mark T, Drescher, Frank, Folz, Rodney J, Hansel, Nadia N, Kalhan, Ravi, Kaner, Robert J, Kanner, Richard E, Krishnan, Jerry A, Lazarus, Stephen C, Maddipati, Veeranna, Martinez, Fernando J, Mathews, Anne, Meldrum, Catherine, McEvoy, Charlene, Nyunoya, Toru, Rogers, Linda, Stringer, William W, Wendt, Christine H, Wise, Robert A, Wisniewski, Stephen R, Sciurba, Frank C, and Woodruff, Prescott G
- Subjects
Lung ,Tobacco ,Clinical Research ,Clinical Trials and Supportive Activities ,Tobacco Smoke and Health ,6.1 Pharmaceuticals ,Evaluation of treatments and therapeutic interventions ,Respiratory ,Good Health and Well Being ,Adrenergic beta-2 Receptor Agonists ,Anti-Bacterial Agents ,Bronchodilator Agents ,Forced Expiratory Volume ,Glucocorticoids ,Glycopyrrolate ,Humans ,Pulmonary Disease ,Chronic Obstructive ,Treatment Outcome ,RETHINC Study Group ,Medical and Health Sciences ,General & Internal Medicine - Abstract
BackgroundMany persons with a history of smoking tobacco have clinically significant respiratory symptoms despite an absence of airflow obstruction as assessed by spirometry. They are often treated with medications for chronic obstructive pulmonary disease (COPD), but supporting evidence for this treatment is lacking.MethodsWe randomly assigned persons who had a tobacco-smoking history of at least 10 pack-years, respiratory symptoms as defined by a COPD Assessment Test score of at least 10 (scores range from 0 to 40, with higher scores indicating worse symptoms), and preserved lung function on spirometry (ratio of forced expiratory volume in 1 second [FEV1] to forced vital capacity [FVC] ≥0.70 and FVC ≥70% of the predicted value after bronchodilator use) to receive either indacaterol (27.5 μg) plus glycopyrrolate (15.6 μg) or placebo twice daily for 12 weeks. The primary outcome was at least a 4-point decrease (i.e., improvement) in the St. George's Respiratory Questionnaire (SGRQ) score (scores range from 0 to 100, with higher scores indicating worse health status) after 12 weeks without treatment failure (defined as an increase in lower respiratory symptoms treated with a long-acting inhaled bronchodilator, glucocorticoid, or antibiotic agent).ResultsA total of 535 participants underwent randomization. In the modified intention-to-treat population (471 participants), 128 of 227 participants (56.4%) in the treatment group and 144 of 244 (59.0%) in the placebo group had at least a 4-point decrease in the SGRQ score (difference, -2.6 percentage points; 95% confidence interval [CI], -11.6 to 6.3; adjusted odds ratio, 0.91; 95% CI, 0.60 to 1.37; P = 0.65). The mean change in the percent of predicted FEV1 was 2.48 percentage points (95% CI, 1.49 to 3.47) in the treatment group and -0.09 percentage points (95% CI, -1.06 to 0.89) in the placebo group, and the mean change in the inspiratory capacity was 0.12 liters (95% CI, 0.07 to 0.18) in the treatment group and 0.02 liters (95% CI, -0.03 to 0.08) in the placebo group. Four serious adverse events occurred in the treatment group, and 11 occurred in the placebo group; none were deemed potentially related to the treatment or placebo.ConclusionsInhaled dual bronchodilator therapy did not decrease respiratory symptoms in symptomatic, tobacco-exposed persons with preserved lung function as assessed by spirometry. (Funded by the National Heart, Lung, and Blood Institute and others; RETHINC ClinicalTrials.gov number, NCT02867761.).
- Published
- 2022
6. Risk of COPD exacerbation is increased by poor sleep quality and modified by social adversity.
- Author
-
Baugh, Aaron, Buhr, Russell G, Quibrera, Pedro, Barjaktarevic, Igor, Barr, R Graham, Bowler, Russell, Han, Meilan King, Kaufman, Joel D, Koch, Abigail L, Krishnan, Jerry, Labaki, Wassim, Martinez, Fernando J, Mkorombindo, Takudzwa, Namen, Andrew, Ortega, Victor, Paine, Robert, Peters, Stephen P, Schotland, Helena, Sundar, Krishna, Zeidler, Michelle R, Hansel, Nadia N, Woodruff, Prescott G, and Thakur, Neeta
- Subjects
Sleep Research ,Chronic Obstructive Pulmonary Disease ,Lung ,Behavioral and Social Science ,Respiratory ,Good Health and Well Being ,Disease Progression ,Humans ,Pulmonary Disease ,Chronic Obstructive ,Severity of Illness Index ,Sleep Quality ,Sleep Wake Disorders ,sleep quality ,PSQI ,exacerbations ,COPD ,health disparities ,Biological Sciences ,Medical and Health Sciences ,Psychology and Cognitive Sciences ,Neurology & Neurosurgery - Abstract
Study objectivesSleep is an important dimension in the care of chronic obstructive pulmonary disease (COPD), but its relevance to exacerbations is unclear. We wanted to assess whether sleep quality as measured by the Pittsburgh Sleep Quality Index (PSQI) is associated with an increased risk of COPD exacerbations and does this differ by socio-environmental exposures.MethodsWe included 1647 current and former smokers with spirometrically confirmed COPD from the SPIROMICS cohort. We assessed incidence rate ratios for exacerbation using zero-inflated negative binomial regression adjusting for demographics, medical comorbidities, and multiple metrics of disease severity, including respiratory medications, airflow obstruction, and symptom burden. Our final model adjusted for socio-environmental exposures using the Area Deprivation Index, a composite measure of contemporary neighborhood quality, and Adversity-Opportunity Index, a composite measure of individual-level historic and current socioeconomic indicators. We used a pre-determined threshold of 20% missingness to undertake multiple imputation by chained equations. As sensitivity analyses, we repeated models in those with complete data and after controlling for prior exacerbations. As an exploratory analysis, we considered an interaction between socio-environmental condition and sleep quality.ResultsAfter adjustment for all co-variates, increasing PSQI scores (range 0-21) were associated with a 5% increased risk for exacerbation per point (p = .001) in the imputed dataset. Sensitivity analyses using complete cases and after controlling for prior exacerbation history were similar. Exploratory analysis suggested less effect among those who lived in poor-quality neighborhoods (p-for-interaction = .035).ConclusionsPoor sleep quality may contribute to future exacerbations among patients with COPD. This represents one target for improving disease control.Clinical trial registrationSubpopulations and Intermediate Outcome Measures in COPD Study (SPIROMICS). ClinicalTrials.gov Identifier# NCT01969344. Registry URL: https://clinicaltrials.gov/ct2/show/.
- Published
- 2022
7. Ambient ozone effects on respiratory outcomes among smokers modified by neighborhood poverty: An analysis of SPIROMICS AIR
- Author
-
Belz, Daniel C, Woo, Han, Putcha, Nirupama, Paulin, Laura M, Koehler, Kirsten, Fawzy, Ashraf, Alexis, Neil E, Barr, R Graham, Comellas, Alejandro P, Cooper, Christopher B, Couper, David, Dransfield, Mark, Gassett, Amanda J, Han, MeiLan, Hoffman, Eric A, Kanner, Richard E, Krishnan, Jerry A, Martinez, Fernando J, Paine, Robert, Peng, Roger D, Peters, Stephen, Pirozzi, Cheryl S, Woodruff, Prescott G, Kaufman, Joel D, Hansel, Nadia N, and Investigators, SPIROMICS
- Subjects
Epidemiology ,Public Health ,Health Sciences ,Climate-Related Exposures and Conditions ,Behavioral and Social Science ,Lung ,Clinical Research ,Health Disparities ,Chronic Obstructive Pulmonary Disease ,Respiratory ,No Poverty ,Air Pollutants ,Air Pollution ,Cohort Studies ,Environmental Exposure ,Humans ,Middle Aged ,Ozone ,Poverty ,Pulmonary Disease ,Chronic Obstructive ,Smokers ,Air pollution ,Chronic obstructive pulmonary disease ,Socioeconomic factors ,Poverty areas ,SPIROMICS Investigators ,Environmental Sciences - Abstract
BackgroundNeighborhood poverty has been associated with poor health outcomes. Previous studies have also identified adverse respiratory effects of long-term ambient ozone. Factors associated with neighborhood poverty may accentuate the adverse impact of ozone on respiratory health.ObjectivesTo evaluate whether neighborhood poverty modifies the association between ambient ozone exposure and respiratory morbidity including symptoms, exacerbation risk, and radiologic parameters, among participants of the SPIROMICS AIR cohort study.MethodsSpatiotemporal models incorporating cohort-specific monitoring estimated 10-year average outdoor ozone concentrations at participants' homes. Adjusted regression models were used to determine the association of ozone exposure with respiratory outcomes, accounting for demographic factors, education, individual income, body mass index (BMI), and study site. Neighborhood poverty rate was defined by percentage of families living below federal poverty level per census tract. Interaction terms for neighborhood poverty rate with ozone were included in covariate-adjusted models to evaluate for effect modification.Results1874 participants were included in the analysis, with mean (± SD) age 64 (± 8.8) years and FEV1 (forced expiratory volume in one second) 74.7% (±25.8) predicted. Participants resided in neighborhoods with mean poverty rate of 9.9% (±10.3) of families below the federal poverty level and mean 10-year ambient ozone concentration of 24.7 (±5.2) ppb. There was an interaction between neighborhood poverty rate and ozone concentration for numerous respiratory outcomes, including COPD Assessment Test score, modified Medical Research Council Dyspnea Scale, six-minute walk test, and odds of COPD exacerbation in the year prior to enrollment, such that adverse effects of ozone were greater among participants in higher poverty neighborhoods.ConclusionIndividuals with COPD in high poverty neighborhoods have higher susceptibility to adverse respiratory effects of ambient ozone exposure, after adjusting for individual factors. These findings highlight the interaction between exposures associated with poverty and their effect on respiratory health.
- Published
- 2022
8. Changes in Spirometry Interpretative Strategies: Implications for Classifying COPD and Predicting Exacerbations
- Author
-
Brems, J. Henry, Balasubramanian, Aparna, Raju, Sarath, Putcha, Nirupama, Fawzy, Ashraf, Hansel, Nadia N., Wise, Robert A., and McCormack, Meredith C.
- Published
- 2024
- Full Text
- View/download PDF
9. Estimating ambient air pollutant concentrations outside and inside homes in the Subpopulations and Intermediate outcomes in COPD air pollution (SPIROMICS air) cohort
- Author
-
Kirwa, Kipruto, Gassett, Amanda J., Sack, Coralynn, Paulin, Laura M., Pirozzi, Cheryl S., Barr, R. Graham, Woodruff, Prescott G., Han, MeiLan, Wilgus, May-Lin, Barjaktarevic, Igor, Peters, Stephen, Hansel, Nadia N., and Kaufman, Joel D.
- Published
- 2024
- Full Text
- View/download PDF
10. Identification of Sputum Biomarkers Predictive of Pulmonary Exacerbations in COPD
- Author
-
Esther, Charles R, O’Neal, Wanda K, Anderson, Wayne H, Kesimer, Mehmet, Ceppe, Agathe, Doerschuk, Claire M, Alexis, Neil E, Hastie, Annette T, Barr, R Graham, Bowler, Russell P, Wells, J Michael, Oelsner, Elizabeth C, Comellas, Alejandro P, Tesfaigzi, Yohannes, Kim, Victor, Paulin, Laura M, Cooper, Christopher B, Han, MeiLan K, Huang, Yvonne J, Labaki, Wassim W, Curtis, Jeffrey L, Boucher, Richard C, Study, Subpopulations and Intermediate Outcome Measures in COPD, Arjomandi, Mehrdad, Barjaktarevic, Igor, Bateman, Lori A, Bhatt, Surya P, Bleecker, Eugene R, Christenson, Stephanie A, Couper, David J, Criner, Gerard J, Crystal, Ronald G, Dransfield, Mark T, Drummond, Brad, Freeman, Christine M, Galban, Craig, Hansel, Nadia N, Hoffman, Eric A, Huang, Yvonne, Kaner, Robert J, Kanner, Richard E, Kleerup, Eric C, Krishnan, Jerry A, LaVange, Lisa M, Lazarus, Stephen C, Martinez, Fernando J, Meyers, Deborah A, Moore, Wendy C, Newell, John D, Paine, Robert, Paulin, Laura, Peters, Stephen P, Pirozzi, Cheryl, Putcha, Nirupama, Ortega, Victor E, Raman, Sanjeev, Rennard, Stephen I, Tashkin, Donald P, Wise, Robert A, and Woodruff, Prescott G
- Subjects
Lung ,Chronic Obstructive Pulmonary Disease ,Clinical Research ,Respiratory ,Good Health and Well Being ,Biomarkers ,Humans ,Hypoxanthines ,N-Acetylneuraminic Acid ,Pulmonary Disease ,Chronic Obstructive ,Sputum ,adenosine ,glutathione ,inflammation ,metabolomics ,methionine salvage ,mucus ,Subpopulations and Intermediate Outcome Measures in COPD Study ,Clinical Sciences ,Respiratory System - Abstract
BackgroundImproved understanding of the pathways associated with airway pathophysiologic features in COPD will identify new predictive biomarkers and novel therapeutic targets.Research questionWhich physiologic pathways are altered in the airways of patients with COPD and will predict exacerbations?Study design and methodsWe applied a mass spectrometric panel of metabolomic biomarkers related to mucus hydration and inflammation to sputa from the multicenter Subpopulations and Intermediate Outcome Measures in COPD Study. Biomarkers elevated in sputa from patients with COPD were evaluated for relationships to measures of COPD disease severity and their ability to predict future exacerbations.ResultsSputum supernatants from 980 patients were analyzed: 77 healthy nonsmokers, 341 smokers with preserved spirometry, and 562 patients with COPD (178 with Global Initiative on Chronic Obstructive Lung Disease [GOLD] stage 1 disease, 303 with GOLD stage 2 disease, and 81 with GOLD stage 3 disease) were analyzed. Biomarkers from multiple pathways were elevated in COPD and correlated with sputum neutrophil counts. Among the most significant analytes (false discovery rate, 0.1) were sialic acid, hypoxanthine, xanthine, methylthioadenosine, adenine, and glutathione. Sialic acid and hypoxanthine were associated strongly with measures of disease severity, and elevation of these biomarkers was associated with shorter time to exacerbation and improved prediction models of future exacerbations.InterpretationBiomarker evaluation implicated pathways involved in mucus hydration, adenosine metabolism, methionine salvage, and oxidative stress in COPD airway pathophysiologic characteristics. Therapies that target these pathways may be of benefit in COPD, and a simple model adding sputum-soluble phase biomarkers improves prediction of pulmonary exacerbations.Trial registryClinicalTrials.gov; No.: NCT01969344; URL: www.Clinicaltrialsgov.
- Published
- 2022
11. Forced Expiratory Flow at 25%-75% Links COPD Physiology to Emphysema and Disease Severity in the SPIROMICS Cohort.
- Author
-
Ronish, Bonnie E, Couper, David J, Barjaktarevic, Igor Z, Cooper, Christopher B, Kanner, Richard E, Pirozzi, Cheryl S, Kim, Victor, Wells, James M, Han, MeiLan K, Woodruff, Prescott G, Ortega, Victor E, Peters, Stephen P, Hoffman, Eric A, Buhr, Russell G, Dolezal, Brett A, Tashkin, Donald P, Liou, Theodore G, Bateman, Lori A, Schroeder, Joyce D, Martinez, Fernando J, Barr, R Graham, Hansel, Nadia N, Comellas, Alejandro P, Rennard, Stephen I, Arjomandi, Mehrdad, and Paine Iii, Robert
- Subjects
Epidemiology ,Biomedical and Clinical Sciences ,Health Sciences ,Clinical Research ,Lung ,Emphysema ,Chronic Obstructive Pulmonary Disease ,Respiratory ,spirometry ,pulmonary physiology ,emphysema ,FEF25-75% ,mid-flow rate ,functional small airways disease - Abstract
BackgroundForced expiratory volume in 1 second (FEV1) is central to the diagnosis of chronic obstructive pulmonary disease (COPD) but is imprecise in classifying disease burden. We examined the potential of the maximal mid-expiratory flow rate (forced expiratory flow rate between 25% and 75% [FEF25%-75%]) as an additional tool for characterizing pathophysiology in COPD.ObjectiveTo determine whether FEF25%-75% helps predict clinical and radiographic abnormalities in COPD.Study design and methodsThe SubPopulations and InteRediate Outcome Measures In COPD Study (SPIROMICS) enrolled a prospective cohort of 2978 nonsmokers and ever-smokers, with and without COPD, to identify phenotypes and intermediate markers of disease progression. We used baseline data from 2771 ever-smokers from the SPIROMICS cohort to identify associations between percent predicted FEF25%-75% (%predFEF25%-75%) and both clinical markers and computed tomography (CT) findings of smoking-related lung disease.ResultsLower %predFEF25-75% was associated with more severe disease, manifested radiographically by increased functional small airways disease, emphysema (most notably with homogeneous distribution), CT-measured residual volume, total lung capacity (TLC), and airway wall thickness, and clinically by increased symptoms, decreased 6-minute walk distance, and increased bronchodilator responsiveness (BDR). A lower %predFEF25-75% remained significantly associated with increased emphysema, functional small airways disease, TLC, and BDR after adjustment for FEV1 or forced vital capacity (FVC).InterpretationThe %predFEF25-75% provides additional information about disease manifestation beyond FEV1. These associations may reflect loss of elastic recoil and air trapping from emphysema and intrinsic small airways disease. Thus, %predFEF25-75% helps link the anatomic pathology and deranged physiology of COPD.
- Published
- 2022
12. Characterizing COPD Symptom Variability in the Stable State Utilizing the Evaluating Respiratory Symptoms in COPD Instrument.
- Author
-
Krishnan, Jamuna K, Ancy, Kayley M, Oromendia, Clara, Hoffman, Katherine L, Easthausen, Imaani, Leidy, Nancy K, Han, MeiLan K, Bowler, Russell P, Christenson, Stephanie A, Couper, David J, Criner, Gerard J, Curtis, Jeffrey L, Dransfield, Mark T, Hansel, Nadia N, Iyer, Anand S, Paine Iii, Robert, Peters, Stephen P, Wedzicha, Jadwiga A, Woodruff, Prescott G, Ballman, Karla V, Martinez, Fernando J, and SPIROMICS Investigators
- Subjects
SPIROMICS Investigators ,EXACT ,chronic obstructive pulmonary disease ,exacerbations ,patient-reported outcomes ,symptom variation ,Chronic Obstructive Pulmonary Disease ,Lung ,Clinical Research ,Respiratory - Abstract
RationaleIt has been suggested that patients with chronic obstructive pulmonary disease (COPD) experience considerable daily respiratory symptom fluctuation. A standardized measure is needed to quantify and understand the implications of day-to-day symptom variability.ObjectivesTo compare standard deviation with other statistical measures of symptom variability and identify characteristics of individuals with higher symptom variability.MethodsIndividuals in the SubPopulations and InteRmediate Outcome Measures In COPD Study (SPIROMICS) Exacerbations sub-study completed an Evaluating Respiratory Symptoms in COPD (E-RS) daily questionnaire. We calculated within-subject standard deviation (WS-SD) for each patient at week 0 and correlated this with measurements obtained 4 weeks later using Pearson's r and Bland Altman plots. Median WS-SD value dichotomized participants into higher versus lower variability groups. Association between WS-SD and exacerbation risk during 4 follow-up weeks was explored.Measurements and main resultsDiary completion rates were sufficient in 140 (68%) of 205 sub-study participants. Reproducibility (r) of the WS-SD metric from baseline to week 4 was 0.32. Higher variability participants had higher St George's Respiratory Questionnaire (SGRQ) scores (47.3 ± 20.3 versus 39.6 ± 21.5, p=.04) than lower variability participants. Exploratory analyses found no relationship between symptom variability and health care resource utilization-defined exacerbations.ConclusionsWS-SD of the E-RS can be used as a measure of symptom variability in studies of patients with COPD. Patients with higher variability have worse health-related quality of life. WS-SD should be further validated as a measure to understand the implications of symptom variability.
- Published
- 2022
13. Reconsidering the Utility of Race-Specific Lung Function Prediction Equations.
- Author
-
Baugh, Aaron D, Shiboski, Stephen, Hansel, Nadia N, Ortega, Victor, Barjaktarevic, Igor, Barr, R Graham, Bowler, Russell, Comellas, Alejandro P, Cooper, Christopher B, Couper, David, Criner, Gerard, Curtis, Jeffrey L, Dransfield, Mark, Ejike, Chinedu, Han, MeiLan K, Hoffman, Eric, Krishnan, Jamuna, Krishnan, Jerry A, Mannino, David, Paine, Robert, Parekh, Trisha, Peters, Stephen, Putcha, Nirupama, Rennard, Stephen, Thakur, Neeta, and Woodruff, Prescott G
- Subjects
Paediatrics ,Biomedical and Clinical Sciences ,Lung ,Clinical Research ,Chronic Obstructive Pulmonary Disease ,Respiratory ,Forced Expiratory Volume ,Humans ,Pulmonary Disease ,Chronic Obstructive ,Pulmonary Emphysema ,Respiratory Function Tests ,Vital Capacity ,respiratory function tests ,racism ,chronic obstructive pulmonary disease ,health disparities ,Medical and Health Sciences ,Respiratory System ,Cardiovascular medicine and haematology ,Clinical sciences - Abstract
Rationale: African American individuals have worse outcomes in chronic obstructive pulmonary disease (COPD). Objectives: To assess whether race-specific approaches for estimating lung function contribute to racial inequities by failing to recognize pathological decrements and considering them normal. Methods: In a cohort with and at risk for COPD, we assessed whether lung function prediction equations applied in a race-specific versus universal manner better modeled the relationship between FEV1, FVC, and other COPD outcomes, including the COPD Assessment Test, St. George's Respiratory Questionnaire, computed tomography percent emphysema, airway wall thickness, and 6-minute-walk test. We related these outcomes to differences in FEV1 using multiple linear regression and compared predictive performance between fitted models using root mean squared error and Alpaydin's paired F test. Measurements and Main Results: Using race-specific equations, African American individuals were calculated to have better lung function than non-Hispanic White individuals (FEV1, 76.8% vs. 71.8% predicted; P = 0.02). Using universally applied equations, African American individuals were calculated to have worse lung function. Using Hankinson's Non-Hispanic White equation, FEV1 was 64.7% versus 71.8% (P
- Published
- 2022
14. Returning incidentally discovered Hepatitis C RNA-seq results to COPDGene study participants
- Author
-
Silverman, Edwin K., Kim, Arthur Y., Make, Barry J., Regan, Elizabeth A., Morrow, Jarrett D., Hersh, Craig P., O’Brien, James, Crapo, James D., Hansel, Nadia N., Criner, Gerard, Flenaugh, Eric L., Conrad, Douglas, Casaburi, Richard, Bowler, Russell P., Hanania, Nicola A., Barr, R. Graham, Bhatt, Surya P., Sciurba, Frank C., Anzueto, Antonio, Han, MeiLan K., McEvoy, Charlene E., Comellas, Alejandro P., DeMeo, Dawn L., Rosiello, Richard, Curtis, Jeffrey L., Uchida, Tricia, Wilson, Carla, and O’Rourke, P. Pearl
- Published
- 2023
- Full Text
- View/download PDF
15. A blood and bronchoalveolar lavage protein signature of rapid FEV1 decline in smoking-associated COPD
- Author
-
DiLillo, Katarina M., Norman, Katy C., Freeman, Christine M., Christenson, Stephanie A., Alexis, Neil E., Anderson, Wayne H., Barjaktarevic, Igor Z., Barr, R. Graham, Comellas, Alejandro P., Bleecker, Eugene R., Boucher, Richard C., Couper, David J., Criner, Gerard J., Doerschuk, Claire M., Wells, J. Michael, Han, MeiLan K., Hoffman, Eric A., Hansel, Nadia N., Hastie, Annette T., Kaner, Robert J., Krishnan, Jerry A., Labaki, Wassim W., Martinez, Fernando J., Meyers, Deborah A., O’Neal, Wanda K., Ortega, Victor E., Paine, III, Robert, Peters, Stephen P., Woodruff, Prescott G., Cooper, Christopher B., Bowler, Russell P., Curtis, Jeffrey L., and Arnold, Kelly B.
- Published
- 2023
- Full Text
- View/download PDF
16. Comparative Impact of Depressive Symptoms and FEV1% on Chronic Obstructive Pulmonary Disease.
- Author
-
O’Toole, Jacqueline, Woo, Han, Putcha, Nirupama, Cooper, Christopher B, Woodruff, Prescott, Kanner, Richard E, Paine, Robert, Bowler, Russell P, Comellas, Alejandro, Hoth, Karin F, Krishnan, Jerry A, Han, Meilan, Dransfield, Mark, Iyer, Anand S, Couper, David, Peters, Stephen P, Criner, Gerard, Kim, Victor, Barr, R Graham, Martinez, Fernando J, Hansel, Nadia N, Eakin, Michelle N, Alexis, Neil E, Anderson, Wayne H, Arjomandi, Mehrdad, Barjaktarevic, Igor, Bateman, Lori A, Bhatt, Surya P, Bleecker, Eugene R, Boucher, Richard C, Christenson, Stephanie A, Comellas, Alejandro P, Couper, David J, Criner, Gerard J, Crystal, Ronald G, Curtis, Jeffrey L, Doerschuk, Claire M, Dransfield, Mark T, Drummond, Brad, Freeman, Christine M, Galban, Craig, Han, MeiLan K, Hastie, Annette T, Hoffman, Eric A, Huang, Yvonne, Kaner, Robert J, Kleerup, Eric C, LaVange, Lisa M, Lazarus, Stephen C, Meyers, Deborah A, Moore, Wendy C, Newell, John D, Paulin, Laura, Pirozzi, Cheryl, Oelsner, Elizabeth C, O’Neal, Wanda K, Ortega, Victor E, Raman, Sanjeev, Rennard, Stephen I, Tashkin, Donald P, Wells, J Michael, Wise, Robert A, and Woodruff, Prescott G
- Subjects
Clinical Research ,Behavioral and Social Science ,Depression ,Chronic Obstructive Pulmonary Disease ,Mental Health ,Lung ,Respiratory ,Good Health and Well Being ,Female ,Forced Expiratory Volume ,Humans ,Pulmonary Disease ,Chronic Obstructive ,Quality of Life ,Respiratory Function Tests ,Smoking ,Surveys and Questionnaires ,depression ,COPD ,patient reported outcome measures ,SPIROMICS Investigators - Abstract
Rationale: Individuals with chronic obstructive pulmonary disease (COPD) have a high prevalence of depression, which is associated with increased COPD hospitalizations and readmissions. Objectives: Examine the impact of depressive symptoms compared with FEV1% on COPD morbidity. Methods: Using longitudinal data from individuals with COPD in the Subpopulations and Intermediate Outcome Measures in COPD Study, longitudinal growth analysis was performed to assess COPD morbidity by assessing differences in baseline 6-minute walk distance and patient reported outcomes (PROs) and their rate of change over time explained by depressive symptoms or lung function, as measured by Hospital Anxiety and Depression Scale or FEV1% respectively. PROs consisted of in-person completion of St. George's Respiratory Questionnaire, COPD Assessment Test, Functional Assessment of Chronic Illness Therapy Fatigue, and Modified Medical Research Council Dyspnea Scale measures. Results: Of the individuals analyzed (n = 1,830), 43% were female, 81% Caucasian with mean ± SD age of 65.1 ± 8.1, and 52.7 ± 27.5 pack-years smoking. Mean ± SD FEV1% was 60.9 ± 23.0% and 20% had clinically significant depressive symptoms. Adjusted models showed higher Hospital Anxiety and Depression Scale scores and lower FEV1% each were associated with worse PROs at baseline (P ⩽ 0.001). Depression accounted for more baseline variance in St. George's Respiratory Questionnaire, COPD Assessment Test, and Functional Assessment of Chronic Illness Therapy Fatigue than FEV1%, explaining 30-67% of heterogeneity. FEV1% accounted for more baseline variance in Modified Medical Research Council Dyspnea Scale and 6-minute walk distance than depression, explaining 16-32% of heterogeneity. Depressive symptoms accounted for 3-17% variance in change over time in PROs. In contrast, FEV1% accounted for 1-4% variance over time in PROs. Conclusions: Depression is more strongly associated with many PROs at baseline and their change over time compared with FEV1%. Recognizing and incorporating the impact of depressive symptoms into individualized care may improve COPD outcomes.
- Published
- 2022
17. Guideline Alignment and Medication Concordance in COPD
- Author
-
Case, Meredith A., Boorman, Eric P., Ruvalcaba, Elizabeth, Vest, Michael T., Hansel, Nadia N., Putcha, Nirupama, and Eakin, Michelle N.
- Published
- 2024
- Full Text
- View/download PDF
18. Indoor particulate matter concentrations and air cleaner intervention association with biomarkers in former smokers with COPD
- Author
-
Fawzy, Ashraf, Woo, Han, Raju, Sarath, Belz, Daniel C., Putcha, Nirupama, Williams, Marlene S., McCormack, Meredith C., Kohler, Kirsten, and Hansel, Nadia N.
- Published
- 2024
- Full Text
- View/download PDF
19. Disparities in access to food and chronic obstructive pulmonary disease (COPD)-related outcomes: a cross-sectional analysis
- Author
-
Moughames, Eric, Woo, Han, Galiatsatos, Panagis, Romero-Rivero, Karina, Raju, Sarath, Tejwani, Vickram, Hoffman, Eric A, Comellas, Alejandro P, Ortega, Victor E, Parekh, Trisha, Krishnan, Jerry A, Drummond, Michael B, Couper, David, Buhr, Russell G, Paine, Robert, Kaufman, Joel D, Paulin, Laura M, Putcha, Nirupama, and Hansel, Nadia N
- Subjects
Biomedical and Clinical Sciences ,Cardiovascular Medicine and Haematology ,Lung ,Chronic Obstructive Pulmonary Disease ,Clinical Research ,Respiratory ,Good Health and Well Being ,Aged ,Cross-Sectional Studies ,Female ,Food ,Humans ,Male ,Middle Aged ,Pulmonary Disease ,Chronic Obstructive ,Access ,COPD ,Disparities ,Food desert ,Cardiorespiratory Medicine and Haematology ,Respiratory System ,Cardiovascular medicine and haematology - Abstract
BackgroundMillions of Americans are living in food deserts in the United States, however the role of the local food environment on COPD has not been studied. The aim of this study is to determine the association between food deserts and COPD-related outcomes.MethodIn this cross-sectional analysis we linked data collected from SPIROMICS (SubPopulations and InteRmediate Outcome Measures in COPD Study) between 2010 and 2015 and food desert data, defined as an underserved area that lacks access to affordable healthy foods, from the Food Access Research Atlas. COPD outcomes include percentage of predicted forced expiratory volume in one second (FEV1%), St. George's Respiratory Questionnaire (SGRQ), COPD Assessment Test (CAT), 6-min walk distance test (6MWD), exacerbations, and air trapping. We used generalized linear mixed models to evaluate the association between living in food deserts and respiratory outcomes, adjusting for age, gender, race, education, income, marital status, BMI, smoking status, pack years, and urban status RESULTS: Among 2713 participants, 22% lived in food deserts. Participants living in food deserts were less likely to be white and more likely to have a lower income than those who did not live in food deserts. In the adjusted model controlling for demographics and individual income, living in food deserts was associated lower FEV1% (β = - 2.51, P = 0.046), higher air trapping (β = 2.47, P = 0.008), worse SGRQ (β = 3.48, P = 0.001) and CAT (β = 1.20, P = 0.003) scores, and 56% greater odds of severe exacerbations (P = 0.004). Results were consistent when looking at food access alone, regardless of whether participants lived in low income areas.ConclusionsFindings suggest an independent association between food desert and food access alone with COPD outcomes. Health program planning may benefit from addressing disparities in access to food.
- Published
- 2021
20. Multiethnic genome-wide and HLA association study of total serum IgE level
- Author
-
Daya, Michelle, Cox, Corey, Acevedo, Nathalie, Boorgula, Meher P, Campbell, Monica, Chavan, Sameer, Cho, Michael H, David, Gloria L, Kachroo, Priyadarshini, Lasky-Su, Jessica, Li, Xingnan, McHugh, Caitlin P, Qiao, Dandi, Rafaels, Nicholas, Beck, Lisa A, Bleecker, Eugene R, Caraballo, Luis, Cupples, Adrienne L, Figueiredo, Camila A, Gallo, Richard L, Hanifin, Jon, Hansel, Nadia N, Hata, Tissa R, Hersh, Craig P, Knight-Madden, Jennifer, Leung, Donald YM, Guttman-Yassky, Emma, Meyers, Deborah A, O’Connor, George, Ober, Carole, Ong, Peck Y, Ortega, Victor E, Paller, Amy S, Putcha, Nirupama, Reed, Robert M, Schneider, Lynda C, Silverman, Edwin K, Slifka, Mark K, Spergel, Jonathan M, Vasan, Ramachandran S, Viaud-Martinez, Karine A, Watson, Harold, Weiss, Scott T, Consortium, NHLBI Trans-Omics for Precision Medicine, Ruczinski, Ingo, Beaty, Terri H, Mathias, Rasika A, and Barnes, Kathleen C
- Subjects
Clinical Research ,Genetics ,Lung ,Asthma ,Human Genome ,Aetiology ,2.1 Biological and endogenous factors ,Inflammatory and immune system ,Good Health and Well Being ,Adolescent ,Adult ,Aged ,Child ,Child ,Preschool ,Dermatitis ,Atopic ,Ethnicity ,Female ,Gene Frequency ,Genetic Predisposition to Disease ,Genome-Wide Association Study ,Genotype ,HLA-A2 Antigen ,HLA-DQ beta-Chains ,Humans ,Immunoglobulin E ,Male ,Middle Aged ,National Heart ,Lung ,and Blood Institute (U.S.) ,United States ,Whole Genome Sequencing ,Young Adult ,Total serum IgE ,human leukocyte antigen ,genome-wide association study ,atopic dermatitis ,asthma ,multiethnic ,NHLBI Trans-Omics for Precision Medicine (TOPMed) Consortium ,Immunology ,Allergy - Abstract
BackgroundTotal serum IgE (tIgE) is an important intermediate phenotype of allergic disease. Whole genome genetic association studies across ancestries may identify important determinants of IgE.ObjectiveWe aimed to increase understanding of genetic variants affecting tIgE production across the ancestry and allergic disease spectrum by leveraging data from the National Heart, Lung and Blood Institute Trans-Omics for Precision Medicine program; the Consortium on Asthma among African-ancestry Populations in the Americas (CAAPA); and the Atopic Dermatitis Research Network (N = 21,901).MethodsWe performed genome-wide association within strata of study, disease, and ancestry groups, and we combined results via a meta-regression approach that models heterogeneity attributable to ancestry. We also tested for association between HLA alleles called from whole genome sequence data and tIgE, assessing replication of associations in HLA alleles called from genotype array data.ResultsWe identified 6 loci at genome-wide significance (P < 5 × 10-9), including 4 loci previously reported as genome-wide significant for tIgE, as well as new regions in chr11q13.5 and chr15q22.2, which were also identified in prior genome-wide association studies of atopic dermatitis and asthma. In the HLA allele association study, HLA-A∗02:01 was associated with decreased tIgE level (Pdiscovery = 2 × 10-4; Preplication = 5 × 10-4; Pdiscovery+replication = 4 × 10-7), and HLA-DQB1∗03:02 was strongly associated with decreased tIgE level in Hispanic/Latino ancestry populations (PHispanic/Latino discovery+replication = 8 × 10-8).ConclusionWe performed the largest genome-wide association study and HLA association study of tIgE focused on ancestrally diverse populations and found several known tIgE and allergic disease loci that are relevant in non-European ancestry populations.
- Published
- 2021
21. Genetic and non-genetic factors affecting the expression of COVID-19-relevant genes in the large airway epithelium
- Author
-
Kasela, Silva, Ortega, Victor E, Martorella, Molly, Garudadri, Suresh, Nguyen, Jenna, Ampleford, Elizabeth, Pasanen, Anu, Nerella, Srilaxmi, Buschur, Kristina L, Barjaktarevic, Igor Z, Barr, R Graham, Bleecker, Eugene R, Bowler, Russell P, Comellas, Alejandro P, Cooper, Christopher B, Couper, David J, Criner, Gerard J, Curtis, Jeffrey L, Han, MeiLan K, Hansel, Nadia N, Hoffman, Eric A, Kaner, Robert J, Krishnan, Jerry A, Martinez, Fernando J, McDonald, Merry-Lynn N, Meyers, Deborah A, Paine, Robert, Peters, Stephen P, Castro, Mario, Denlinger, Loren C, Erzurum, Serpil C, Fahy, John V, Israel, Elliot, Jarjour, Nizar N, Levy, Bruce D, Li, Xingnan, Moore, Wendy C, Wenzel, Sally E, Zein, Joe, Langelier, Charles, Woodruff, Prescott G, Lappalainen, Tuuli, and Christenson, Stephanie A
- Subjects
Biological Sciences ,Genetics ,Lung ,Clinical Research ,Infectious Diseases ,Prevention ,Emerging Infectious Diseases ,Human Genome ,2.2 Factors relating to the physical environment ,Aetiology ,2.1 Biological and endogenous factors ,Infection ,Respiratory ,Good Health and Well Being ,Adult ,Aged ,Aged ,80 and over ,Angiotensin-Converting Enzyme 2 ,Asthma ,Bronchi ,COVID-19 ,Cardiovascular Diseases ,Gene Expression ,Genetic Variation ,Humans ,Middle Aged ,Obesity ,Pulmonary Disease ,Chronic Obstructive ,Quantitative Trait Loci ,Respiratory Mucosa ,Risk Factors ,SARS-CoV-2 ,Smoking ,ACE2 ,eQTL ,Bronchial epithelium ,NHLBI SubPopulations and InteRmediate Outcome Measures In COPD Study ,NHLBI Trans-Omics for Precision Medicine (TOPMed) Consortium ,Clinical Sciences - Abstract
BackgroundThe large airway epithelial barrier provides one of the first lines of defense against respiratory viruses, including SARS-CoV-2 that causes COVID-19. Substantial inter-individual variability in individual disease courses is hypothesized to be partially mediated by the differential regulation of the genes that interact with the SARS-CoV-2 virus or are involved in the subsequent host response. Here, we comprehensively investigated non-genetic and genetic factors influencing COVID-19-relevant bronchial epithelial gene expression.MethodsWe analyzed RNA-sequencing data from bronchial epithelial brushings obtained from uninfected individuals. We related ACE2 gene expression to host and environmental factors in the SPIROMICS cohort of smokers with and without chronic obstructive pulmonary disease (COPD) and replicated these associations in two asthma cohorts, SARP and MAST. To identify airway biology beyond ACE2 binding that may contribute to increased susceptibility, we used gene set enrichment analyses to determine if gene expression changes indicative of a suppressed airway immune response observed early in SARS-CoV-2 infection are also observed in association with host factors. To identify host genetic variants affecting COVID-19 susceptibility in SPIROMICS, we performed expression quantitative trait (eQTL) mapping and investigated the phenotypic associations of the eQTL variants.ResultsWe found that ACE2 expression was higher in relation to active smoking, obesity, and hypertension that are known risk factors of COVID-19 severity, while an association with interferon-related inflammation was driven by the truncated, non-binding ACE2 isoform. We discovered that expression patterns of a suppressed airway immune response to early SARS-CoV-2 infection, compared to other viruses, are similar to patterns associated with obesity, hypertension, and cardiovascular disease, which may thus contribute to a COVID-19-susceptible airway environment. eQTL mapping identified regulatory variants for genes implicated in COVID-19, some of which had pheWAS evidence for their potential role in respiratory infections.ConclusionsThese data provide evidence that clinically relevant variation in the expression of COVID-19-related genes is associated with host factors, environmental exposures, and likely host genetic variation.
- Published
- 2021
22. Defining Resilience to Smoking-related Lung Disease: A Modified Delphi Approach from SPIROMICS.
- Author
-
Oh, Anita L, Mularski, Richard A, Barjaktarevic, Igor, Barr, R Graham, Bowler, Russell P, Comellas, Alejandro P, Cooper, Christopher B, Criner, Gerard J, Han, MeiLan K, Hansel, Nadia N, Hoffman, Eric A, Kanner, Richard E, Krishnan, Jerry A, Paine, Robert, Parekh, Trisha M, Peters, Stephen P, Christenson, Stephanie A, Woodruff, Prescott G, and SPIROMICS Smoking Resilience Group
- Subjects
SPIROMICS Smoking Resilience Group ,Lung ,Humans ,Pulmonary Disease ,Chronic Obstructive ,Forced Expiratory Volume ,Spirometry ,Smoking ,biomarkers ,chronic obstructive pulmonary disease ,consensus development ,smoking ,spirometry ,Tobacco ,Tobacco Smoke and Health ,Lung Cancer ,Chronic Obstructive Pulmonary Disease ,Clinical Research ,Cancer ,Respiratory - Abstract
Rationale: Diagnosis of chronic obstructive pulmonary disease (COPD) relies on abnormal spirometry. However, spirometry may underestimate the effects of smoking, missing smokers with respiratory disease who have minimal or no airflow obstruction. Objectives: To develop a multidimensional definition of a lung-related "resilient smoker" that is useful in research studies and then identify a resilient smoker subgroup in the SPIROMICS (SubPopulations and InteRmediate Outcome Measures In COPD Study) cohort using this definition. Methods: We performed a three-round modified Delphi survey among a panel of COPD experts to identify and reach a consensus on clinical and radiographic domains to be included in a lung-related resilient smoker definition. Consensus on domains of resilience was defined as ⩾80% of experts voting "agree" or "strongly agree" on a 5-point Likert scale. The Delphi-derived definition of resilience was applied to SPIROMICS to identify resilient smokers, whom we then characterized using known biomarkers of COPD. Results: Consensus was achieved on 6 of 12 diagnostic items, which include cough and sputum production, dyspnea, radiographic measures of emphysema and small airways disease, exacerbations, and decline in forced expiratory volume in 1 second. Although 892 SPIROMICS participants were classified as smokers with preserved lung function by spirometry, only 149 participants (16.7%) qualified as resilient smokers by our definition. Blood biomarker expression of CRP (C-reactive protein) and sTNFRSF1A (soluble tumor necrosis receptor factor1A) was lower in resilient than nonresilient smokers (P = 0.02 and P = 0.03). Conclusions: A Delphi-derived consensus definition of resilient smoker identified 83.3% of smokers with preserved spirometry as "nonresilient" based on the presence of adverse effects of smoking on the lung. Resilient smokers were biologically distinct from nonresilient smokers based on CRP measurements. Clinical trial registered with ClinicalTrials.gov (NCT01969344).
- Published
- 2021
23. Emphysema Progression and Lung Function Decline Among Angiotensin Converting Enzyme Inhibitors and Angiotensin-Receptor Blockade Users in the COPDGene Cohort
- Author
-
Tejwani, Vickram, Fawzy, Ashraf, Putcha, Nirupama, Castaldi, Peter J, Cho, Michael H, Pratte, Katherine A, Bhatt, Surya P, Lynch, David A, Humphries, Stephen M, Kinney, Gregory L, D’Alessio, Franco R, Hansel, Nadia N, Crapo, James D, Silverman, Edwin K, Make, Barry J, Regan, Elizabeth A, Beaty, Terri, Begum, Ferdouse, Cho, Michael, DeMeo, Dawn L, Boueiz, Adel R, Foreman, Marilyn G, Halper-Stromberg, Eitan, Hayden, Lystra P, Hersh, Craig P, Hetmanski, Jacqueline, Hobbs, Brian D, Hokanson, John E, Laird, Nan, Lange, Christoph, Lutz, Sharon M, McDonald, Merry-Lynn, Parker, Margaret M, Prokopenko, Dmitry, Qiao, Dandi, Regan, Elizabeth, Sakornsakolpat, Phuwanat, Wan, Emily S, Won, Sungho, Centeno, Juan Pablo, Charbonnier, Jean-Paul, Coxson, Harvey O, Galban, Craig J, Han, MeiLan K, Hoffman, Eric A, Humphries, Stephen, Jacobson, Francine L, Judy, Philip F, Kazerooni, Ella A, Kluiber, Alex, Nardelli, Pietro, Newell, John D, Notary, Aleena, Oh, Andrea, Ross, James C, San Jose Estepar, Raul, Schroeder, Joyce, Sieren, Jered, Stoel, Berend C, Tschirren, Juerg, Van Beek, Edwin, Ginneken, Bramvan, van Rikxoort, Eva, Sanchez-Ferrero, Gonzalo Vegas, Veitel, Lucas, Washko, George R, Wilson, Carla G, Jensen, Robert, Everett, Douglas, Crooks, Jim, Pratte, Katherine, Strand, Matt, Kinney, Gregory, Young, Kendra A, Bon, Jessica, Diaz, Alejandro A, Make, Barry, Murray, Susan, Soler, Xavier, Bowler, Russell P, Kechris, Katerina, Banaei-Kashani, Farnoush, Curtis, Jeffrey L, Pernicano, Perry G, Hanania, Nicola, Atik, Mustafa, Boriek, Aladin, Guntupalli, Kalpatha, and Guy, Elizabeth
- Subjects
Biomedical and Clinical Sciences ,Cardiovascular Medicine and Haematology ,Clinical Sciences ,Clinical Research ,Emphysema ,Lung ,Tobacco ,Chronic Obstructive Pulmonary Disease ,Tobacco Smoke and Health ,Cancer ,Respiratory ,Aged ,Angiotensin Receptor Antagonists ,Angiotensin-Converting Enzyme Inhibitors ,Cohort Studies ,Disease Progression ,Female ,Forced Expiratory Volume ,Humans ,Lung Volume Measurements ,Male ,Middle Aged ,Prospective Studies ,Protective Factors ,Pulmonary Disease ,Chronic Obstructive ,Pulmonary Emphysema ,Spirometry ,Tomography ,X-Ray Computed ,Vital Capacity ,Walk Test ,angiotensin II ,COPD ,emphysema progression ,COPDGene Investigators ,Respiratory System ,Cardiovascular medicine and haematology ,Clinical sciences - Abstract
BackgroundAttenuation of transforming growth factor β by blocking angiotensin II has been shown to reduce emphysema in a murine model. General population studies have demonstrated that the use of angiotensin converting enzyme inhibitors (ACEis) and angiotensin-receptor blockers (ARBs) is associated with reduction of emphysema progression in former smokers and that the use of ACEis is associated with reduction of FEV1 progression in current smokers.Research questionIs use of ACEi and ARB associated with less progression of emphysema and FEV1 decline among individuals with COPD or baseline emphysema?MethodsFormer and current smokers from the Genetic Epidemiology of COPD Study who attended baseline and 5-year follow-up visits, did not change smoking status, and underwent chest CT imaging were included. Adjusted linear mixed models were used to evaluate progression of adjusted lung density (ALD), percent emphysema (%total lung volume
- Published
- 2021
24. Haemoglobin as a biomarker for clinical outcomes in chronic obstructive pulmonary disease.
- Author
-
Balasubramanian, Aparna, Henderson, Robert J, Putcha, Nirupama, Fawzy, Ashraf, Raju, Sarath, Hansel, Nadia N, MacIntyre, Neil R, Jensen, Robert L, Kinney, Gregory L, Stringer, William W, Hersh, Craig P, Bowler, Russell P, Casaburi, Richard, Han, MeiLan K, Porszasz, Janos, Make, Barry J, McCormack, Meredith C, and Wise, Robert A
- Abstract
In COPD, anaemia is associated with increased morbidity, but the relationship between haemoglobin over its entire observed range and morbidity is poorly understood. Such an understanding could guide future therapeutic targeting of haemoglobin in COPD management. Leveraging the COPDGene study, we conducted a cross-sectional analysis of haemoglobin from COPD participants, examining symptoms, quality of life, functional performance, and acute exacerbations of COPD (AECOPD). Haemoglobin was analysed both as a continuous variable and categorised into anaemia, normal haemoglobin, and polycythaemia groups. Fractional polynomial modelling was used for continuous analyses; categorical models were multivariable linear or negative binomial regressions. Covariates included demographics, comorbidities, emphysema, diffusing capacity, and airflow obstruction. From 2539 participants, 366 (14%) were identified as anaemic and 125 (5%) as polycythaemic. Compared with normal haemoglobin, anaemia was significantly associated with increased symptoms (COPD Assessment Test score: p=0.006, modified Medical Research Council (mMRC) Dyspnoea Score: p=0.001); worse quality of life (St. George's Respiratory Questionnaire (SGRQ) score: p
- Published
- 2021
25. Ratio of FEV1/Slow Vital Capacity of < 0.7 Is Associated With Clinical, Functional, and Radiologic Features of Obstructive Lung Disease in Smokers With Preserved Lung Function
- Author
-
Fortis, Spyridon, Comellas, Alejandro P, Bhatt, Surya P, Hoffman, Eric A, Han, MeiLan K, Bhakta, Nirav R, Paine, Robert, Ronish, Bonnie, Kanner, Richard E, Dransfield, Mark, Hoesterey, Daniel, Buhr, Russell G, Barr, R Graham, Dolezal, Brett, Ortega, Victor E, Drummond, M Bradley, Arjomandi, Mehrdad, Kaner, Robert J, Kim, Victor, Curtis, Jeffrey L, Bowler, Russell P, Martinez, Fernando, Labaki, Wassim W, Cooper, Christopher B, O'Neal, Wanda K, Criner, Gerald, Hansel, Nadia N, Krishnan, Jerry A, Woodruff, Prescott, Couper, David, Tashkin, Donald, and Barjaktarevic, Igor
- Subjects
Biomedical and Clinical Sciences ,Cardiovascular Medicine and Haematology ,Clinical Sciences ,Clinical Research ,Chronic Obstructive Pulmonary Disease ,Lung ,Respiratory ,Disease Progression ,Follow-Up Studies ,Forced Expiratory Volume ,Humans ,Prospective Studies ,Pulmonary Disease ,Chronic Obstructive ,Smokers ,Spirometry ,Tomography ,X-Ray Computed ,Vital Capacity ,COPD ,pulmonary ,pulmonary function test ,slow vital capacity ,SVC ,Respiratory System ,Cardiovascular medicine and haematology ,Clinical sciences - Abstract
BackgroundMild expiratory flow limitation may not be recognized using traditional spirometric criteria based on the ratio of FEV1/FVC.Research questionDoes slow vital capacity (SVC) instead of FVC increase the sensitivity of spirometry to identify patients with early or mild obstructive lung disease?Study design and methodsWe included 854 current and former smokers from the Subpopulations and Intermediate Outcome Measures in COPD Study cohort with a postbronchodilator FEV1/FVC ≥ 0.7 and FEV1 % predicted of ≥ 80% at enrollment. We compared baseline characteristics, chest CT scan features, exacerbations, and progression to COPD (postbronchodilator FEV1/FVC, < 0.7) during the follow-up period between 734 participants with postbronchodilator FEV1/SVC of ≥ 0.7 and 120 with postbronchodilator FEV1/SVC < 0.7 at the enrollment. We performed multivariate linear and logistic regression models and negative binomial and interval-censored proportion hazards regression models adjusted for demographics and smoking exposure to examine the association of FEV1/SVC < 0.7 with those characteristics and outcomes.ResultsParticipants with FEV1/SVC < 0.7 were older and had lower FEV1 and more emphysema than those with FEV1/SVC ≥ 0.7. In adjusted analysis, individuals with postbronchodilator FEV1/SVC < 0.7 showed a greater percentage of emphysema by 0.45% (95% CI, 0.09%-0.82%), percentage of gas trapping by 2.52% (95% CI, 0.59%-4.44%), and percentage of functional small airways disease based on parametric response mapping by 2.78% (95% CI, 0.72%-4.83%) at baseline than those with FEV1/SVC ≥ 0.7. During a median follow-up time of 1,500 days, an FEV1/SVC < 0.7 was not associated with total exacerbations (incident rate ratio [IRR], 1.61; 95% CI, 0.97-2.64), but was associated with severe exacerbations (IRR, 2.60; 95% CI, 1.04-4.89). An FEV1/SVC < 0.7 was associated with progression to COPD during a 3-year follow-up even after adjustment for demographics and smoking exposure (hazard ratio, 3.93; 95% CI, 2.71-5.72). We found similar results when we examined the association of prebronchodilator FEV1/SVC < 0.7 or FEV1/SVC less than the lower limit of normal with chest CT scan features and progression to COPD.InterpretationLow FEV1 to SVC in current and former smokers with normal spirometry results can identify individuals with CT scan features of COPD who are at risk for severe exacerbations and is associated with progression to COPD in the future.Trial registryClinicalTrials.gov; No.: NCT01969344T4; URL: www.clinicaltrials.gov.
- Published
- 2021
26. Contribution of Individual and Neighborhood Factors to Racial Disparities in Respiratory Outcomes.
- Author
-
Ejike, Chinedu O, Woo, Han, Galiatsatos, Panagis, Paulin, Laura M, Krishnan, Jerry A, Cooper, Christopher B, Couper, David J, Kanner, Richard E, Bowler, Russell P, Hoffman, Eric A, Comellas, Alejandro P, Criner, Gerard J, Barr, R Graham, Martinez, Fernando J, Han, MeiLan K, Martinez, Carlos H, Ortega, Victor E, Parekh, Trisha M, Christenson, Stephanie A, Thakur, Neeta, Baugh, Aaron, Belz, Daniel C, Raju, Sarath, Gassett, Amanda J, Kaufman, Joel D, Putcha, Nirupama, and Hansel, Nadia N
- Subjects
Lung ,Clinical Research ,Behavioral and Social Science ,Chronic Obstructive Pulmonary Disease ,Respiratory ,Adult ,Black or African American ,Aged ,Aged ,80 and over ,Female ,Health Status Disparities ,Healthcare Disparities ,Humans ,Male ,Middle Aged ,Outcome Assessment ,Health Care ,Pulmonary Disease ,Chronic Obstructive ,Race Factors ,Smoking ,Social Class ,Socioeconomic Factors ,Surveys and Questionnaires ,White People ,COPD ,racial disparities ,socioeconomic status ,neighborhood disadvantage ,Medical and Health Sciences ,Respiratory System - Abstract
Rationale: Black adults have worse health outcomes compared with white adults in certain chronic diseases, including chronic obstructive pulmonary disease (COPD).Objectives: To determine to what degree disadvantage by individual and neighborhood socioeconomic status (SES) may contribute to racial disparities in COPD outcomes.Methods: Individual and neighborhood-scale sociodemographic characteristics were determined in 2,649 current or former adult smokers with and without COPD at recruitment into SPIROMICS (Subpopulations and Intermediate Outcome Measures in COPD Study). We assessed whether racial differences in symptom, functional, and imaging outcomes (St. George's Respiratory Questionnaire, COPD Assessment Test score, modified Medical Research Council dyspnea scale, 6-minute-walk test distance, and computed tomography [CT] scan metrics) and severe exacerbation risk were explained by individual or neighborhood SES. Using generalized linear mixed model regression, we compared respiratory outcomes by race, adjusting for confounders and individual-level and neighborhood-level descriptors of SES both separately and sequentially.Measurements and Main Results: After adjusting for COPD risk factors, Black participants had significantly worse respiratory symptoms and quality of life (modified Medical Research Council scale, COPD Assessment Test, and St. George's Respiratory Questionnaire), higher risk of severe exacerbations and higher percentage of emphysema, thicker airways (internal perimeter of 10 mm), and more air trapping on CT metrics compared with white participants. In addition, the association between Black race and respiratory outcomes was attenuated but remained statistically significant after adjusting for individual-level SES, which explained up to 12-35% of racial disparities. Further adjustment showed that neighborhood-level SES explained another 26-54% of the racial disparities in respiratory outcomes. Even after accounting for both individual and neighborhood SES factors, Black individuals continued to have increased severe exacerbation risk and persistently worse CT outcomes (emphysema, air trapping, and airway wall thickness).Conclusions: Disadvantages by individual- and neighborhood-level SES each partly explain disparities in respiratory outcomes between Black individuals and white individuals. Strategies to narrow the gap in SES disadvantages may help to reduce race-related health disparities in COPD; however, further work is needed to identify additional risk factors contributing to persistent disparities.
- Published
- 2021
27. Mucus Plugs and Emphysema in the Pathophysiology of Airflow Obstruction and Hypoxemia in Smokers.
- Author
-
Dunican, Eleanor M, Elicker, Brett M, Henry, Travis, Gierada, David S, Schiebler, Mark L, Anderson, Wayne, Barjaktarevic, Igor, Barr, R Graham, Bleecker, Eugene R, Boucher, Richard C, Bowler, Russell, Christenson, Stephanie A, Comellas, Alejandro, Cooper, Christopher B, Couper, David, Criner, Gerard J, Dransfield, Mark, Doerschuk, Claire M, Drummond, M Bradley, Hansel, Nadia N, Han, MeiLan K, Hastie, Annette T, Hoffman, Eric A, Krishnan, Jerry A, Lazarus, Stephen C, Martinez, Fernando J, McCulloch, Charles E, O'Neal, Wanda K, Ortega, Victor E, Paine, Robert, Peters, Stephen, Schroeder, Joyce D, Woodruff, Prescott G, and Fahy, John V
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Chronic Obstructive Pulmonary Disease ,Clinical Research ,Emphysema ,Clinical Trials and Supportive Activities ,Lung ,Respiratory ,Aged ,Female ,Forced Expiratory Volume ,Healthy Volunteers ,Humans ,Hypoxia ,Male ,Middle Aged ,Mucus ,Pulmonary Disease ,Chronic Obstructive ,Pulmonary Emphysema ,Respiratory Function Tests ,Smokers ,Smoking ,Vital Capacity ,COPD ,computed tomography ,FEV1 ,mucus plugs ,emphysema ,Medical and Health Sciences ,Respiratory System ,Cardiovascular medicine and haematology ,Clinical sciences - Abstract
Rationale: The relative roles of mucus plugs and emphysema in mechanisms of airflow limitation and hypoxemia in smokers with chronic obstructive pulmonary disease (COPD) are uncertain.Objectives: To relate image-based measures of mucus plugs and emphysema to measures of airflow obstruction and oxygenation in patients with COPD.Methods: We analyzed computed tomographic (CT) lung images and lung function in participants in the Subpopulations and Intermediate Outcome Measures in COPD Study. Radiologists scored mucus plugs on CT lung images, and imaging software automatically quantified emphysema percentage. Unadjusted and adjusted relationships between mucus plug score, emphysema percentage, and lung function were determined using regression.Measurements and Main Results: Among 400 smokers, 229 (57%) had mucus plugs and 207 (52%) had emphysema, and subgroups could be identified with mucus-dominant and emphysema-dominant disease. Only 33% of smokers with high mucus plug scores had mucus symptoms. Mucus plug score and emphysema percentage were independently associated with lower values for FEV1 and peripheral oxygen saturation (P
- Published
- 2021
28. Evaluation of calibration approaches for indoor deployments of PurpleAir monitors
- Author
-
Koehler, Kirsten, Wilks, Megan, Green, Timothy, Rule, Ana M., Zamora, Misti L., Buehler, Colby, Datta, Abhirup, Gentner, Drew R., Putcha, Nirupama, Hansel, Nadia N., Kirk, Gregory D., Raju, Sarath, and McCormack, Meredith
- Published
- 2023
- Full Text
- View/download PDF
29. E-Cigarettes and Cardiopulmonary Health
- Author
-
Tarran, Robert, Barr, R Graham, Benowitz, Neal L, Bhatnagar, Aruni, Chu, Hong W, Dalton, Pamela, Doerschuk, Claire M, Drummond, M Bradley, Gold, Diane R, Goniewicz, Maciej L, Gross, Eric R, Hansel, Nadia N, Hopke, Philip K, Kloner, Robert A, Mikheev, Vladimir B, Neczypor, Evan W, Pinkerton, Kent E, Postow, Lisa, Rahman, Irfan, Samet, Jonathan M, Salathe, Matthias, Stoney, Catherine M, Tsao, Philip S, Widome, Rachel, Xia, Tian, Xiao, DaLiao, and Wold, Loren E
- Subjects
Medical Physiology ,Biomedical and Clinical Sciences ,Tobacco ,Pediatric ,Electronic Nicotine Delivery Systems ,Prevention ,Cardiovascular ,Generic health relevance ,Good Health and Well Being ,Adolescent ,Young Adult ,Humans ,Nicotine ,Tobacco Products ,Lung ,Cardiovascular Diseases ,e-cigarette ,cardiovascular disease ,pulmonary disease ,policy ,cessation ,Medical physiology - Abstract
E-cigarettes have surged in popularity over the last few years, particularly among youth and young adults. These battery-powered devices aerosolize e-liquids, comprised of propylene glycol and vegetable glycerin, typically with nicotine, flavors, and stabilizers/humectants. Although the use of combustible cigarettes is associated with several adverse health effects including multiple pulmonary and cardiovascular diseases, the effects of e-cigarettes on both short- and long-term health have only begun to be investigated. Given the recent increase in the popularity of e-cigarettes, there is an urgent need for studies to address their potential adverse health effects, particularly as many researchers have suggested that e-cigarettes may pose less of a health risk than traditional combustible cigarettes and should be used as nicotine replacements. This report is prepared for clinicians, researchers, and other health care providers to provide the current state of knowledge on how e-cigarette use might affect cardiopulmonary health, along with research gaps to be addressed in future studies.
- Published
- 2021
30. Longitudinal Imaging-Based Clusters in Former Smokers of the COPD Cohort Associate with Clinical Characteristics: The SubPopulations and Intermediate Outcome Measures in COPD Study (SPIROMICS)
- Author
-
Zou, Chunrui, Li, Frank, Choi, Jiwoong, Haghighi, Babak, Choi, Sanghun, Rajaraman, Prathish K, Comellas, Alejandro P, Newell, John D, Lee, Chang Hyun, Barr, R Graham, Bleecker, Eugene, Cooper, Christopher B, Couper, David, Han, Meilan, Hansel, Nadia N, Kanner, Richard E, Kazerooni, Ella A, Kleerup, Eric C, Martinez, Fernando J, O’Neal, Wanda, Paine, Robert, Rennard, Stephen I, Smith, Benjamin M, Woodruff, Prescott G, Hoffman, Eirc A, and Lin, Ching-Long
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Clinical Research ,Chronic Obstructive Pulmonary Disease ,Lung ,Biomedical Imaging ,Respiratory ,Cross-Sectional Studies ,Humans ,Outcome Assessment ,Health Care ,Pulmonary Disease ,Chronic Obstructive ,Pulmonary Emphysema ,Smokers ,computed tomography ,emphysema ,functional small airway disease ,longitudinal clustering ,Cardiorespiratory Medicine and Haematology ,Respiratory System ,Cardiovascular medicine and haematology - Abstract
PurposeQuantitative computed tomography (qCT) imaging-based cluster analysis identified clinically meaningful COPD former-smoker subgroups (clusters) based on cross-sectional data. We aimed to identify progression clusters for former smokers using longitudinal data.Patients and methodsWe selected 472 former smokers from SPIROMICS with a baseline visit and a one-year follow-up visit. A total of 150 qCT imaging-based variables, comprising 75 variables at baseline and their corresponding progression rates, were derived from the respective inspiration and expiration scans of the two visits. The COPD progression clusters identified were then associated with subject demography, clinical variables and biomarkers.ResultsCOPD severities at baseline increased with increasing cluster number. Cluster 1 patients were an obese subgroup with rapid progression of functional small airway disease percentage (fSAD%) and emphysema percentage (Emph%). Cluster 2 exhibited a decrease of fSAD% and Emph%, an increase of tissue fraction at total lung capacity and airway narrowing over one year. Cluster 3 showed rapid expansion of Emph% and an attenuation of fSAD%. Cluster 4 demonstrated severe emphysema and fSAD and significant structural alterations at baseline with rapid progression of fSAD% over one year. Subjects with different progression patterns in the same cross-sectional cluster were identified by longitudinal clustering.ConclusionqCT imaging-based metrics at two visits for former smokers allow for the derivation of four statistically stable clusters associated with unique progression patterns and clinical characteristics. Use of baseline variables and their progression rates enables identification of longitudinal clusters, resulting in a refinement of cross-sectional clusters.
- Published
- 2021
31. Cardiopulmonary Impact of Particulate Air Pollution in High-Risk Populations JACC State-of-the-Art Review
- Author
-
Newman, Jonathan D, Bhatt, Deepak L, Rajagopalan, Sanjay, Balmes, John R, Brauer, Michael, Breysse, Patrick N, Brown, Alison GM, Carnethon, Mercedes R, Cascio, Wayne E, Collman, Gwen W, Fine, Lawrence J, Hansel, Nadia N, Hernandez, Adrian, Hochman, Judith S, Jerrett, Michael, Joubert, Bonnie R, Kaufman, Joel D, Malik, Ali O, Mensah, George A, Newby, David E, Peel, Jennifer L, Siegel, Jeffrey, Siscovick, David, Thompson, Betsy L, Zhang, Junfeng, and Brook, Robert D
- Subjects
Biomedical and Clinical Sciences ,Cardiovascular Medicine and Haematology ,Climate-Related Exposures and Conditions ,Clinical Research ,Clinical Trials and Supportive Activities ,Prevention ,Aetiology ,2.2 Factors relating to the physical environment ,Generic health relevance ,Good Health and Well Being ,Air Pollution ,Clinical Trials as Topic ,Education ,Heart Diseases ,Humans ,Lung Diseases ,Particulate Matter ,cardiopulmonary disease ,cardiovascular disease ,fine particulate air pollution ,portable air cleaner ,randomized clinical trials ,Cardiorespiratory Medicine and Haematology ,Public Health and Health Services ,Cardiovascular System & Hematology ,Cardiovascular medicine and haematology - Abstract
Fine particulate air pollution
- Published
- 2020
32. Clinical Phenotypes of Atopy and Asthma in COPD A Meta-analysis of SPIROMICS and COPDGene
- Author
-
Putcha, Nirupama, Fawzy, Ashraf, Matsui, Elizabeth C, Liu, Mark C, Bowler, Russ P, Woodruff, Prescott G, O'Neal, Wanda K, Comellas, Alejandro P, Han, MeiLan K, Dransfield, Mark T, Wells, J Michael, Lugogo, Njira, Gao, Li, Talbot, C Conover, Hoffman, Eric A, Cooper, Christopher B, Paulin, Laura M, Kanner, Richard E, Criner, Gerard, Ortega, Victor E, Barr, R Graham, Krishnan, Jerry A, Martinez, Fernando J, Drummond, M Bradley, Wise, Robert A, Diette, Gregory B, Hersh, Craig P, and Hansel, Nadia N
- Subjects
Biomedical and Clinical Sciences ,Cardiovascular Medicine and Haematology ,Clinical Sciences ,Tobacco Smoke and Health ,Lung ,Clinical Research ,Tobacco ,Asthma ,Chronic Obstructive Pulmonary Disease ,Respiratory ,Asthma-Chronic Obstructive Pulmonary Disease Overlap Syndrome ,Biological Variation ,Population ,Disease Management ,Female ,Humans ,Hypersensitivity ,Immediate ,Immunoglobulin E ,Male ,Middle Aged ,Molecular Epidemiology ,Prevalence ,Pulmonary Disease ,Chronic Obstructive ,Risk Factors ,Smoking ,Status Asthmaticus ,asthma COPD overlap ,atopy ,COPD ,Respiratory System ,Cardiovascular medicine and haematology ,Clinical sciences - Abstract
BackgroundLittle is known about the concordance of atopy with asthma COPD overlap. Among individuals with COPD, a better understanding of the phenotypes characterized by asthma overlap and atopy is needed to better target therapies.Research questionWhat is the overlap between atopy and asthma status among individuals with COPD, and how are categories defined by the presence of atopy and asthma status associated with clinical and radiologic phenotypes and outcomes in the Genetic Epidemiology of COPD Study (COPDGene) and Subpopulation and Intermediate Outcome Measures in COPD Study (SPIROMICS)?Study design and methodsFour hundred three individuals with COPD from SPIROMICS and 696 individuals from COPDGene with data about specific IgEs to 10 common allergens and mixes (simultaneous assessment of combination of allergens in similar category) were included. Comparison groups were defined by atopic and asthma status (neither, atopy alone, atopic asthma, nonatopic asthma, with atopy defined as any positive specific IgE (≥0.35 KU/L) to any of the 10 allergens or mixes and asthma defined as self-report of doctor-diagnosed current asthma). Multivariable regression analyses (linear, logistic, and zero inflated negative binomial where appropriate) adjusted for age, sex, race, lung function, smoking status, pack-years smoked, and use of inhaled corticosteroids were used to determine characteristics of groups and relationship with outcomes (exacerbations, clinical outcomes, CT metrics) separately in COPDGene and SPIROMICS, and then adjusted results were combined using meta-analysis.ResultsThe prevalence of atopy was 35% and 36% in COPD subjects from SPIROMICS and COPDGene, respectively, and less than 50% overlap was seen between atopic status with asthma in both cohorts. In meta-analysis, individuals with nonatopic asthma had the most impaired symptom scores (effect size for St. George's Respiratory Questionnaire total score, 4.2; 95% CI, 0.4-7.9; effect size for COPD Assessment Test score, 2.8; 95% CI, 0.089-5.4), highest risk for exacerbations (incidence rate ratio, 1.41; 95% CI, 1.05-1.88) compared with the group without atopy or asthma. Those with atopy and atopic asthma were not at increased risk for adverse outcomes.InterpretationAsthma and atopy had incomplete overlap among former and current smokers with COPD in COPDGene and SPIROMICS. Nonatopic asthma was associated with adverse outcomes and exacerbation risk in COPD, whereas groups having atopy alone and atopic asthma had less risk.
- Published
- 2020
33. A cross sectional pilot study to assess the role of phthalates on respiratory morbidity among patients with chronic obstructive pulmonary disease
- Author
-
Quirós-Alcalá, Lesliam, Belz, Daniel C., Woo, Han, Lorizio, Wendy, Putcha, Nirupama, Koehler, Kirsten, McCormack, Meredith C., and Hansel, Nadia N.
- Published
- 2023
- Full Text
- View/download PDF
34. Reduced quantity and function of pneumococcal antibodies are associated with exacerbations of COPD in SPIROMICS
- Author
-
LaFon, David C., Woo, Han, Fedarko, Neal, Azar, Antoine, Hill, Harry, Tebo, Anne E., Martins, Thomas B., Han, MeiLan K., Krishnan, Jerry A., Ortega, Victor E., Barjaktarevic, Igor, Kaner, Robert J., Hastie, Annette, O'Neal, Wanda K., Couper, David, Woodruff, Prescott G., Curtis, Jeffrey L., Hansel, Nadia N., Nahm, Moon H., Dransfield, Mark T., and Putcha, Nirupama
- Published
- 2023
- Full Text
- View/download PDF
35. Principal stratification analysis to determine health benefit of indoor air pollution reduction in a randomized environmental intervention in COPD: Results from the CLEAN AIR study
- Author
-
Woo, Han, Koehler, Kirsten, Putcha, Nirupama, Lorizio, Wendy, McCormack, Meredith, Peng, Roger, and Hansel, Nadia N.
- Published
- 2023
- Full Text
- View/download PDF
36. Increased airway iron parameters and risk for exacerbation in COPD: an analysis from SPIROMICS.
- Author
-
Zhang, William Z, Oromendia, Clara, Kikkers, Sarah Ann, Butler, James J, O'Beirne, Sarah, Kim, Kihwan, O'Neal, Wanda K, Freeman, Christine M, Christenson, Stephanie A, Peters, Stephen P, Wells, J Michael, Doerschuk, Claire, Putcha, Nirupama, Barjaktarevic, Igor, Woodruff, Prescott G, Cooper, Christopher B, Bowler, Russell P, Comellas, Alejandro P, Criner, Gerard J, Paine, Robert, Hansel, Nadia N, Han, Meilan K, Crystal, Ronald G, Kaner, Robert J, Ballman, Karla V, Curtis, Jeffrey L, Martinez, Fernando J, and Cloonan, Suzanne M
- Subjects
Lung ,Bronchoalveolar Lavage Fluid ,Humans ,Pulmonary Disease ,Chronic Obstructive ,Disease Progression ,Iron ,Iron-Binding Proteins ,Respiratory Function Tests ,Forced Expiratory Volume ,Severity of Illness Index ,Risk Factors ,Adult ,Aged ,Aged ,80 and over ,Middle Aged ,Female ,Male ,Ferritins ,Biomarkers - Abstract
Levels of iron and iron-related proteins including ferritin are higher in the lung tissue and lavage fluid of individuals with chronic obstructive pulmonary disease (COPD), when compared to healthy controls. Whether more iron in the extracellular milieu of the lung associates with distinct clinical phenotypes of COPD, including increased exacerbation susceptibility, is unknown. We measured iron and ferritin levels in the bronchoalveolar lavage fluid (BALF) of participants enrolled in the SubPopulations and InteRmediate Outcome Measures In COPD (SPIROMICS) bronchoscopy sub-study (n = 195). BALF Iron parameters were compared to systemic markers of iron availability and tested for association with FEV1 % predicted and exacerbation frequency. Exacerbations were modelled using a zero-inflated negative binomial model using age, sex, smoking, and FEV1 % predicted as clinical covariates. BALF iron and ferritin were higher in participants with COPD and in smokers without COPD when compared to non-smoker control participants but did not correlate with systemic iron markers. BALF ferritin and iron were elevated in participants who had COPD exacerbations, with a 2-fold increase in BALF ferritin and iron conveying a 24% and 2-fold increase in exacerbation risk, respectively. Similar associations were not observed with plasma ferritin. Increased airway iron levels may be representative of a distinct pathobiological phenomenon that results in more frequent COPD exacerbation events, contributing to disease progression in these individuals.
- Published
- 2020
37. Associations Among 25-Hydroxyvitamin D Levels, Lung Function, and Exacerbation Outcomes in COPD: An Analysis of the SPIROMICS Cohort.
- Author
-
Burkes, Robert M, Ceppe, Agathe S, Doerschuk, Claire M, Couper, David, Hoffman, Eric A, Comellas, Alejandro P, Barr, R Graham, Krishnan, Jerry A, Cooper, Christopher, Labaki, Wassim W, Ortega, Victor E, Wells, J Michael, Criner, Gerard J, Woodruff, Prescott G, Bowler, Russell P, Pirozzi, Cheryl S, Hansel, Nadia N, Wise, Robert A, Brown, Todd T, Drummond, M Bradley, and SPIROMICS Investigators
- Subjects
SPIROMICS Investigators ,Humans ,Pulmonary Disease ,Chronic Obstructive ,Vitamin D Deficiency ,Disease Progression ,Vitamin D ,Respiratory Function Tests ,Prevalence ,Longitudinal Studies ,Middle Aged ,United States ,Female ,Male ,Biomarkers ,Symptom Flare Up ,Correlation of Data ,Outcome Assessment ,Health Care ,COPD ,COPD epidemiology ,COPD exacerbations ,lung function ,vitamin D ,Nutrition ,Complementary and Integrative Health ,Lung ,Clinical Research ,Chronic Obstructive Pulmonary Disease ,Underpinning research ,1.1 Normal biological development and functioning ,Respiratory ,Clinical Sciences ,Respiratory System - Abstract
BackgroundThe relationship between 25-hydroxyvitamin D (25-OH-vitamin D) and COPD outcomes remains unclear. Using the Subpopulations and Intermediate Outcome Measures in COPD Study (SPIROMICS), we determined associations among baseline 25-OH-vitamin D and cross-sectional and longitudinal lung function and COPD exacerbations.MethodsSerum 25-OH-vitamin D level was measured in stored samples from 1,609 SPIROMICS participants with COPD. 25-OH-vitamin D levels were modeled continuously and dichotomized as deficient (< 20 ng/mL) vs not deficient (≥ 20 ng/mL). Outcomes of interest included % predicted FEV1 (current and 1-year longitudinal decline) and COPD exacerbations (separately any and severe, occurring in prior year and first year of follow-up).ResultsVitamin D deficiency was present in 21% of the cohort and was more prevalent in the younger, active smokers, and blacks. Vitamin D deficiency was independently associated with lower % predicted FEV1 (by 4.11%) at enrollment (95% CI, -6.90% to -1.34% predicted FEV1; P = .004), 1.27% predicted greater rate of FEV1 decline after 1 year (95% CI, -2.32% to -0.22% predicted/y; P = .02), and higher odds of any COPD exacerbation in the prior year (OR, 1.32; 95% CI, 1.00-1.74; P = .049). Each 10-ng/mL decrease in 25-OH-vitamin D was associated with lower baseline lung function (-1.04% predicted; 95% CI, -1.96% to -0.12% predicted; P = .03) and increased odds of any exacerbation in the year before enrollment (OR, 1.11; 95% CI, 1.01-1.22; P = .04).ConclusionsVitamin D deficiency is associated with worse cross-sectional and longitudinal lung function and increased odds of prior COPD exacerbations. These findings identify 25-OH-vitamin D levels as a potentially useful marker of adverse COPD-related outcomes.
- Published
- 2020
38. The Effects of Rare SERPINA1 Variants on Lung Function and Emphysema in SPIROMICS
- Author
-
Ortega, Victor E, Li, Xingnan, O’Neal, Wanda K, Lackey, Lela, Ampleford, Elizabeth, Hawkins, Gregory A, Grayeski, Philip J, Laederach, Alain, Barjaktarevic, Igor, Barr, R Graham, Cooper, Christopher, Couper, David, Han, MeiLan K, Kanner, Richard E, Kleerup, Eric C, Martinez, Fernando J, Paine, Robert, Peters, Stephen P, Pirozzi, Cheryl, Rennard, Stephen I, Woodruff, Prescott G, Hoffman, Eric A, Meyers, Deborah A, Bleecker, Eugene R, Alexis, Neil E, Anderson, Wayne H, Arjomandi, Mehrdad, Bateman, Lori A, Bhatt, Surya P, Boucher, Richard C, Bowler, Russell P, Christenson, Stephanie A, Comellas, Alejandro P, Criner, Gerard J, Crystal, Ronald G, Curtis, Jeffrey L, Doerschuk, Claire M, Dransfield, Mark T, Freeman, Christine M, Galban, Craig, Hansel, Nadia N, Hastie, Annette T, Huang, Yvonne, Kaner, Robert J, Krishnan, Jerry A, LaVange, Lisa M, Lazarus, Stephen C, Moore, Wendy C, Paulin, Laura, Putcha, Nirupama, Oelsner, Elizabeth C, Raman, Sanjeev, Tashkin, Donald P, Wells, J Michael, and Wise, Robert A
- Subjects
Biomedical and Clinical Sciences ,Cardiovascular Medicine and Haematology ,Clinical Sciences ,Tobacco ,Emphysema ,Clinical Research ,Genetics ,Tobacco Smoke and Health ,Lung ,Chronic Obstructive Pulmonary Disease ,2.1 Biological and endogenous factors ,Aetiology ,Respiratory ,Adult ,Black or African American ,Aged ,Aged ,80 and over ,Female ,Forced Expiratory Volume ,Genotype ,Heterozygote ,Hispanic or Latino ,Humans ,Isoelectric Focusing ,Male ,Maximal Midexpiratory Flow Rate ,Middle Aged ,Phenotype ,Polymorphism ,Genetic ,Pulmonary Disease ,Chronic Obstructive ,Pulmonary Emphysema ,Smoking ,Tomography ,X-Ray Computed ,Vital Capacity ,White People ,alpha 1-Antitrypsin ,chronic obstructive pulmonary disease ,alpha-1 antitrypsin ,SERPINA1 ,rare variant ,emphysema ,NHLBI Subpopulations and Intermediate Outcomes Measures in COPD Study ,Medical and Health Sciences ,Respiratory System ,Cardiovascular medicine and haematology ,Clinical sciences - Abstract
Rationale: The role of PI (protease inhibitor) type Z heterozygotes and additional rare variant genotypes in the gene encoding alpha-1 antitrypsin, SERPINA1 (serpin peptidase inhibitor, clade A, member 1), in determining chronic obstructive pulmonary disease risk and severity is controversial.Objectives: To comprehensively evaluate the effects of rare SERPINA1 variants on lung function and emphysema phenotypes in subjects with significant tobacco smoke exposure using deep gene resequencing and alpha-1 antitrypsin concentrations.Methods: DNA samples from 1,693 non-Hispanic white individuals, 385 African Americans, and 90 Hispanics with ≥20 pack-years smoking were resequenced for the identification of rare variants (allele frequency
- Published
- 2020
39. The Association Between Neighborhood Socioeconomic Disadvantage and Chronic Obstructive Pulmonary Disease
- Author
-
Galiatsatos, Panagis, Woo, Han, Paulin, Laura M, Kind, Amy, Putcha, Nirupama, Gassett, Amanda J, Cooper, Christopher B, Dransfield, Mark T, Parekh, Trisha M, Oates, Gabriela R, Barr, R Graham, Comellas, Alejandro P, Han, Meilan K, Peters, Stephen P, Krishnan, Jerry A, Labaki, Wassim W, McCormack, Meredith C, Kaufman, Joel D, and Hansel, Nadia N
- Subjects
Biomedical and Clinical Sciences ,Cardiovascular Medicine and Haematology ,Prevention ,Clinical Research ,Behavioral and Social Science ,Chronic Obstructive Pulmonary Disease ,Lung ,Clinical Trials and Supportive Activities ,Respiratory ,Body Mass Index ,Humans ,Pulmonary Disease ,Chronic Obstructive ,Residence Characteristics ,Social Class ,Socioeconomic Factors ,health disparities ,COPD ,area deprivation index ,Cardiorespiratory Medicine and Haematology ,Respiratory System ,Cardiovascular medicine and haematology - Abstract
RationaleIndividual socioeconomic status has been shown to influence the outcomes of patients with chronic obstructive pulmonary disease (COPD). However, contextual factors may also play a role. The objective of this study is to evaluate the association between neighborhood socioeconomic disadvantage measured by the area deprivation index (ADI) and COPD-related outcomes.MethodsResidential addresses of SubPopulations and InteRmediate Outcome Measures in COPD Study (SPIROMICS) subjects with COPD (FEV1/FVC
- Published
- 2020
40. Defining Chronic Mucus Hypersecretion Using the CAT in the SPIROMICS Cohort
- Author
-
Stott-Miller, Marni, Müllerová, Hana, Miller, Bruce, Tabberer, Maggie, Baou, Céline El, Keeley, Tom, Martinez, Fernando J, Han, Meilan, Dransfield, Mark, Hansel, Nadia N, Cooper, Christopher B, Woodruff, Prescott, Ortega, Victor E, Comellas, Alejandro P, Paine, Robert, Kanner, Richard E, Anderson, Wayne, Drummond, M Bradley, Kim, Victor, Tal-Singer, Ruth, and Lazaar, Aili L
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Lung ,Clinical Research ,Chronic Obstructive Pulmonary Disease ,Respiratory ,Bronchitis ,Chronic ,Female ,Humans ,Male ,Mucus ,Pulmonary Disease ,Chronic Obstructive ,Quality of Life ,Respiratory Function Tests ,Surveys and Questionnaires ,COPD ,SGRQ ,exacerbation ,CAT ,cough ,phlegm ,Cardiorespiratory Medicine and Haematology ,Respiratory System ,Cardiovascular medicine and haematology - Abstract
BackgroundChronic cough and phlegm are frequently reported chronic obstructive pulmonary disease (COPD) symptoms. Prior research classified chronic mucus hypersecretion (CMH) based on the presence of these symptoms for ≥3 months, called chronic bronchitis (CB) if respiratory infection symptoms were present for 1-2 years (Medical Research Council [MRC] definition). We explored whether the COPD Assessment Test (CAT), a simple measure developed for routine clinical use, captures CMH populations and outcomes similarly to MRC and St. George's Respiratory Questionnaire (SGRQ) definitions.MethodsWe identified CMH in the SPIROMICS COPD cohort using (a) MRC definitions, (b) SGRQ questions for cough and phlegm (both as most/several days a week), and (c) CAT cough and phlegm questions. We determined optimal cut-points for CAT items and described exacerbation frequencies for different CMH definitions. Moderate exacerbations required a new prescription for antibiotics/oral corticosteroids or emergency department visit; severe exacerbations required hospitalization. Results were stratified by smoking status.ResultsIn a population of 1431 participants (57% male; mean FEV1% predicted 61%), 47% and 49% of evaluable participants had SGRQ- or CAT-defined CMH, respectively. A cut-point of ≥2 for cough and phlegm items defined CMH in CAT. Among SGRQ-CMH+ participants, 80% were also defined as CMH+ by the CAT. CMH+ participants were more likely to be current smokers. A higher exacerbation frequency was observed for presence of CMH+ versus CMH- in the year prior to baseline for all CMH definitions; this trend continued across 3 years of follow-up, regardless of smoking status.ConclusionItems from the CAT identified SGRQ-defined CMH, a frequent COPD trait that correlated with exacerbation frequency. The CAT is a short, simple questionnaire and a potentially valuable tool for telemedicine or real-world trials. CAT-based CMH is a novel approach for identifying clinically important characteristics in COPD that can be ascertained in these settings.
- Published
- 2020
41. Novel Respiratory Disability Score Predicts COPD Exacerbations and Mortality in the SPIROMICS Cohort
- Author
-
Cooper, Christopher B, Paine, Robert, Curtis, Jeffrey L, Kanner, Richard E, Martinez, Carlos H, Meldrum, Catherine A, Bowler, Russell, O’Neal, Wanda, Hoffman, Eric A, Couper, David, Quibrera, Miguel, Criner, Gerald, Dransfield, Mark T, Han, MeiLan K, Hansel, Nadia N, Krishnan, Jerry A, Lazarus, Stephen C, Peters, Stephen P, Barr, R Graham, Martinez, Fernando J, and Woodruff, Prescott G
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Clinical Research ,Tobacco Smoke and Health ,Chronic Obstructive Pulmonary Disease ,Tobacco ,Lung ,Respiratory ,Good Health and Well Being ,Cohort Studies ,Dyspnea ,Female ,Humans ,Male ,Pulmonary Disease ,Chronic Obstructive ,Surveys and Questionnaires ,disability ,frailty ,exacerbation rate ,mortality ,SPIROMICS ,SPIROMICS investigators ,Cardiorespiratory Medicine and Haematology ,Respiratory System ,Cardiovascular medicine and haematology - Abstract
RationaleSome COPD patients develop extreme breathlessness, decreased exercise capacity and poor health status yet respiratory disability is poorly characterized as a distinct phenotype.ObjectiveTo define respiratory disability in COPD based on available functional measures and to determine associations with risk for exacerbations and death.MethodsWe analyzed baseline data from a multi-center observational study (SPIROMICS). This analysis includes 2332 participants (472 with severe COPD, 991 with mild/moderate COPD, 726 smokers without airflow obstruction and 143 non-smoking controls).MeasurementsWe defined respiratory disability by ≥4 of 7 criteria: mMRC dyspnea scale ≥3; Veterans Specific Activity Questionnaire 60; COPD Assessment Test >20; fatigue (FACIT-F Trial Outcome Index)
- Published
- 2020
42. COPDGene® 2019: Redefining the Diagnosis of Chronic Obstructive Pulmonary Disease.
- Author
-
Lowe, Katherine E, Regan, Elizabeth A, Anzueto, Antonio, Austin, Erin, Austin, John HM, Beaty, Terri H, Benos, Panayiotis V, Benway, Christopher J, Bhatt, Surya P, Bleecker, Eugene R, Bodduluri, Sandeep, Bon, Jessica, Boriek, Aladin M, Boueiz, Adel Re, Bowler, Russell P, Budoff, Matthew, Casaburi, Richard, Castaldi, Peter J, Charbonnier, Jean-Paul, Cho, Michael H, Comellas, Alejandro, Conrad, Douglas, Costa Davis, Corinne, Criner, Gerard J, Curran-Everett, Douglas, Curtis, Jeffrey L, DeMeo, Dawn L, Diaz, Alejandro A, Dransfield, Mark T, Dy, Jennifer G, Fawzy, Ashraf, Fleming, Margaret, Flenaugh, Eric L, Foreman, Marilyn G, Fortis, Spyridon, Gebrekristos, Hirut, Grant, Sarah, Grenier, Philippe A, Gu, Tian, Gupta, Abhya, Han, MeiLan K, Hanania, Nicola A, Hansel, Nadia N, Hayden, Lystra P, Hersh, Craig P, Hobbs, Brian D, Hoffman, Eric A, Hogg, James C, Hokanson, John E, Hoth, Karin F, Hsiao, Albert, Humphries, Stephen, Jacobs, Kathleen, Jacobson, Francine L, Kazerooni, Ella A, Kim, Victor, Kim, Woo Jin, Kinney, Gregory L, Koegler, Harald, Lutz, Sharon M, Lynch, David A, MacIntye, Neil R, Make, Barry J, Marchetti, Nathaniel, Martinez, Fernando J, Maselli, Diego J, Mathews, Anne M, McCormack, Meredith C, McDonald, Merry-Lynn N, McEvoy, Charlene E, Moll, Matthew, Molye, Sarah S, Murray, Susan, Nath, Hrudaya, Newell, John D, Occhipinti, Mariaelena, Paoletti, Matteo, Parekh, Trisha, Pistolesi, Massimo, Pratte, Katherine A, Putcha, Nirupama, Ragland, Margaret, Reinhardt, Joseph M, Rennard, Stephen I, Rosiello, Richard A, Ross, James C, Rossiter, Harry B, Ruczinski, Ingo, San Jose Estepar, Raul, Sciurba, Frank C, Sieren, Jessica C, Singh, Harjinder, Soler, Xavier, Steiner, Robert M, Strand, Matthew J, Stringer, William W, Tal-Singer, Ruth, Thomashow, Byron, Vegas Sánchez-Ferrero, Gonzalo, and Walsh, John W
- Subjects
COPD Genetic Epidemiology study ,preserved ratio-impaired spirometry ,COPD diagnosis ,COPD diagnosis ,COPDGene ,GOLD ,Global initiative for chronic Obstructive Lung Dis ,PRISm ,chronic obstructive pulmonary disease ,copd ,preserved ratio-impaired spirometry ,spirometry ,Prevention ,Tobacco Smoke and Health ,Tobacco ,Lung ,Chronic Obstructive Pulmonary Disease ,Biomedical Imaging ,Clinical Research ,4.2 Evaluation of markers and technologies ,Detection ,screening and diagnosis ,4.1 Discovery and preclinical testing of markers and technologies ,Respiratory ,Good Health and Well Being ,COPD ,COPD Genetic Epidemiology study ,Global initiative for chronic Obstructive Lung Disease - Abstract
BackgroundChronic obstructive pulmonary disease (COPD) remains a major cause of morbidity and mortality. Present-day diagnostic criteria are largely based solely on spirometric criteria. Accumulating evidence has identified a substantial number of individuals without spirometric evidence of COPD who suffer from respiratory symptoms and/or increased morbidity and mortality. There is a clear need for an expanded definition of COPD that is linked to physiologic, structural (computed tomography [CT]) and clinical evidence of disease. Using data from the COPD Genetic Epidemiology study (COPDGene®), we hypothesized that an integrated approach that includes environmental exposure, clinical symptoms, chest CT imaging and spirometry better defines disease and captures the likelihood of progression of respiratory obstruction and mortality.MethodsFour key disease characteristics - environmental exposure (cigarette smoking), clinical symptoms (dyspnea and/or chronic bronchitis), chest CT imaging abnormalities (emphysema, gas trapping and/or airway wall thickening), and abnormal spirometry - were evaluated in a group of 8784 current and former smokers who were participants in COPDGene® Phase 1. Using these 4 disease characteristics, 8 categories of participants were identified and evaluated for odds of spirometric disease progression (FEV1 > 350 ml loss over 5 years), and the hazard ratio for all-cause mortality was examined.ResultsUsing smokers without symptoms, CT imaging abnormalities or airflow obstruction as the reference population, individuals were classified as Possible COPD, Probable COPD and Definite COPD. Current Global initiative for obstructive Lung Disease (GOLD) criteria would diagnose 4062 (46%) of the 8784 study participants with COPD. The proposed COPDGene® 2019 diagnostic criteria would add an additional 3144 participants. Under the new criteria, 82% of the 8784 study participants would be diagnosed with Possible, Probable or Definite COPD. These COPD groups showed increased risk of disease progression and mortality. Mortality increased in patients as the number of their COPD characteristics increased, with a maximum hazard ratio for all cause-mortality of 5.18 (95% confidence interval [CI]: 4.15-6.48) in those with all 4 disease characteristics.ConclusionsA substantial portion of smokers with respiratory symptoms and imaging abnormalities do not manifest spirometric obstruction as defined by population normals. These individuals are at significant risk of death and spirometric disease progression. We propose to redefine the diagnosis of COPD through an integrated approach using environmental exposure, clinical symptoms, CT imaging and spirometric criteria. These expanded criteria offer the potential to stimulate both current and future interventions that could slow or halt disease progression in patients before disability or irreversible lung structural changes develop.
- Published
- 2019
43. Prevalence of abnormal spirometry in individuals with a smoking history and no known obstructive lung disease
- Author
-
Crapo, James D., Silverman, Edwin K., Make, Barry J., Regan, Elizabeth A., Beaty, Terri H., Castaldi, Peter J., Cho, Michael H., DeMeo, Dawn L., El Boueiz, Adel, Foreman, Marilyn G., Ghosh, Auyon, Hayden, Lystra P., Hersh, Craig P., Hetmanski, Jacqueline, Hobbs, Brian D., Hokanson, John E., Kim, Wonji, Laird, Nan, Lange, Christoph, Lutz, Sharon M., McDonald, Merry-Lynn, Prokopenko, Dmitry, Moll, Matthew, Morrow, Jarrett, Qiao, Dandi, Saferali, Aabida, Sakornsakolpat, Phuwanat, Wan, Emily S., Yun, Jeong, Centeno, Juan Pablo, Charbonnier, Jean-Paul, Coxson, Harvey O., Galban, Craig J., Han, MeiLan K., Hoffman, Eric A., Humphries, Stephen, Jacobson, Francine L., Judy, Philip F., Kazerooni, Ella A., Kluiber, Alex, Lynch, David A., Nardelli, Pietro, Newell, John D., Jr., Notary, Aleena, Oh, Andrea, Ross, James C., San Jose Estepar, Raul, Schroeder, Joyce, Sieren, Jered, Stoel, Berend C., Tschirren, Juerg, Van Beek, Edwin, van Ginneken, Bram, van Rikxoort, Eva, Sanchez Ferrero, Gonzalo Vegas, Veitel, Lucas, Washko, George R., Wilson, Carla G., Jensen, Robert, Everett, Douglas, Crooks, Jim, Pratte, Katherine, Strand, Matt, Austin, Erin, Kinney, Gregory, Young, Kendra A., Bhatt, Surya P., Bon, Jessica, Diaz, Alejandro A., Make, Barry, Murray, Susan, Regan, Elizabeth, Soler, Xavier, Bowler, Russell P., Kechris, Katerina, BanaeiKashani, Farnoush, Curtis, Jeffrey L., Pernicano, Perry G., Hanania, Nicola, Atik, Mustafa, Boriek, Aladin, Guntupalli, Kalpatha, Guy, Elizabeth, Parulekar, Amit, Hersh, Craig, Washko, George, Barr, R. Graham, Austin, John, D'Souza, Belinda, Thomashow, Byron, MacIntyre, Neil, Jr., McAdams, H. Page, Washington, Lacey, McEvoy, Charlene, Tashjian, Joseph, Wise, Robert, Brown, Robert, Hansel, Nadia N., Horton, Karen, Lambert, Allison, Putcha, Nirupama, Casaburi, Richard, Adami, Alessandra, Budoff, Matthew, Fischer, Hans, Porszasz, Janos, Rossiter, Harry, Stringer, William, Sharafkhaneh, Amir, Lan, Charlie, Wendt, Christine, Bell, Brian, Kunisaki, Ken M., Flenaugh, Eric L., Gebrekristos, Hirut, Ponce, Mario, Terpenning, Silanath, Westney, Gloria, Bowler, Russell, Rosiello, Richard, Pace, David, Criner, Gerard, Ciccolella, David, Cordova, Francis, Dass, Chandra, D'Alonzo, Gilbert, Desai, Parag, Jacobs, Michael, Kelsen, Steven, Kim, Victor, Mamary, A. James, Marchetti, Nathaniel, Satti, Aditi, Shenoy, Kartik, Steiner, Robert M., Swift, Alex, Swift, Irene, Vega-Sanchez, Maria Elena, Dransfield, Mark, Bailey, William, Iyer, Anand, Nath, Hrudaya, Wells, J. Michael, Conrad, Douglas, Yen, Andrew, Comellas, Alejandro P., Hoth, Karin F., Newell, John, Jr., Thompson, Brad, Kazerooni, Ella, Labaki, Wassim, Galban, Craig, Vummidi, Dharshan, Billings, Joanne, Begnaud, Abbie, Allen, Tadashi, Sciurba, Frank, Chandra, Divay, Weissfeld, Joel, Anzueto, Antonio, Adams, Sandra, Maselli-Caceres, Diego, Ruiz, Mario E., Singh, Harjinder, Tran, Thuonghien V., Kinney, Gregory L., Comellas, Alejandro, Baldomero, Arianne K., Hokanson, John, and Fortis, Spyridon
- Published
- 2023
- Full Text
- View/download PDF
44. Bronchodilator Responsiveness in Tobacco-Exposed People With or Without COPD
- Author
-
Alexis, Neil E., Anderson, Wayne H., Arjomandi, Mehrdad, Barjaktarevic, Igor, Barr, R. Graham, Basta, Patricia, Bateman, Lori A., Bhatt, Surya P., Bleecker, Eugene R., Boucher, Richard C., Bowler, Russell P., Christenson, Stephanie A., Comellas, Alejandro P., Cooper, Christopher B., Couper, David J., Criner, Gerard J., Crystal, Ronald G., Curtis, Jeffrey L., Doerschuk, Claire M., Dransfield, Mark T., Drummond, Brad, Freeman, Christine M., Galban, Craig, Han, MeiLan K., Hansel, Nadia N., Hastie, Annette T., Hoffman, Eric A., Huang, Yvonne, Kaner, Robert J., Kanner, Richard E., Kleerup, Eric C., Krishnan, Jerry A., LaVange, Lisa M., Lazarus, Stephen C., Martinez, Fernando J., Meyers, Deborah A., Moore, Wendy C., Newell, John D., Jr., Paine, Robert, III, Paulin, Laura, Peters, Stephen P., Pirozzi, Cheryl, Putcha, Nirupama, Oelsner, Elizabeth C., O’Neal, Wanda K., Ortega, Victor E., Raman, Sanjeev, Rennard, Stephen I., Tashkin, Donald P., Wells, J. Michael, Wise, Robert A., Woodruff, Prescott G., Fortis, Spyridon, Quibrera, Pedro M., Dransfield, Mark B., Dolezal, Brett A., Kim, Victor, Barjaktarevic, Igor Z., and Couper, David
- Published
- 2023
- Full Text
- View/download PDF
45. Clinical Markers Associated With Risk of Suicide or Drug Overdose Among Individuals With Smoking Exposure: A Longitudinal Follow-up Study of the COPDGene Cohort
- Author
-
Crapo, James D., Silverman, Edwin K., Make, Barry J., Regan, Elizabeth A., Beaty, Terri H., Castaldi, Peter J., Cho, Michael H., DeMeo, Dawn L., El Boueiz, Adel, Foreman, Marilyn G., Ghosh, Auyon, Hayden, Lystra P., Hersh, Craig P., Hetmanski, Jacqueline, Hobbs, Brian D., Hokanson, John E., Kim, Wonji, Laird, Nan, Lange, Christoph, Lutz, Sharon M., McDonald, Merry-Lynn, Prokopenko, Dmitry, Moll, Matthew, Morrow, Jarrett, Qiao, Dandi, Saferali, Aabida, Sakornsakolpat, Phuwanat, Wan, Emily S., Yun, Jeong, Centeno, Juan Pablo, Charbonnier, Jean-Paul, Coxson, Harvey O., Galban, Craig J., Han, MeiLan K., Hoffman, Eric A., Humphries, Stephen, Jacobson, Francine L., Judy, Philip F., Kazerooni, Ella A., Kluiber, Alex, Lynch, David A., Nardelli, Pietro, Newell, John D., Jr., Notary, Aleena, Oh, Andrea, Ross, James C., San Jose Estepar, Raul, Schroeder, Joyce, Sieren, Jered, Stoel, Berend C., Tschirren, Juerg, Van Beek, Edwin, van Ginneken, Bram, van Rikxoort, Eva, Sanchez-Ferrero, Gonzalo Vegas, Veitel, Lucas, Washko, George R., Wilson, Carla G., Jensen, Robert, Strand, Matthew, Crooks, Jim, Pratte, Katherine, Khatiwada, Aastha, Austin, Erin, Kinney, Gregory, Young, Kendra A., Bhatt, Surya P., Bon, Jessica, Diaz, Alejandro A., Make, Barry, Murray, Susan, Regan, Elizabeth, Soler, Xavier, Bowler, Russell P., Kechris, Katerina, Banaei-Kashani, Farnoush, Curtis, Jeffrey L., Pernicano, Perry G., Hanania, Nicola, Atik, Mustafa, Boriek, Aladin, Guntupalli, Kalpatha, Guy, Elizabeth, Parulekar, Amit, Hersh, Craig, Washko, George, Barr, R. Graham, Austin, John, D’Souza, Belinda, Thomashow, Byron, MacIntyre, Neil, Jr., McAdams, H. Page, Washington, Lacey, McEvoy, Charlene, Tashjian, Joseph, Wise, Robert, Brown, Robert, Hansel, Nadia N., Horton, Karen, Lambert, Allison, Putcha, Nirupama, Casaburi, Richard, Adami, Alessandra, Budoff, Matthew, Fischer, Hans, Porszasz, Janos, Rossiter, Harry, Stringer, William, Sharafkhaneh, Amir, Lan, Charlie, Wendt, Christine, Bell, Brian, Kunisaki, Ken M., Flenaugh, Eric L., Gebrekristos, Hirut, Ponce, Mario, Terpenning, Silanath, Westney, Gloria, Bowler, Russell, Rosiello, Richard, Pace, David, Criner, Gerard, Ciccolella, David, Cordova, Francis, Dass, Chandra, D’Alonzo, Gilbert, Desai, Parag, Jacobs, Michael, Kelsen, Steven, Kim, Victor, Mamary, A. James, Marchetti, Nathaniel, Satti, Aditi, Shenoy, Kartik, Steiner, Robert M., Swift, Alex, Swift, Irene, Vega-Sanchez, Maria Elena, Dransfield, Mark, Bailey, William, Iyer, Anand, Nath, Hrudaya, Wells, J. Michael, Conrad, Douglas, Yen, Andrew, Comellas, Alejandro P., Hoth, Karin F., Newell, John, Jr., Thompson, Brad, Kazerooni, Ella, Labaki, Wassim, Galban, Craig, Vummidi, Dharshan, Billings, Joanne, Begnaud, Abbie, Allen, Tadashi, Sciurba, Frank, Chandra, Divay, Weissfeld, Joel, Anzueto, Antonio, Adams, Sandra, Maselli-Caceres, Diego, Ruiz, Mario E., Singh, Harjinder, Adviento, Brigid A., Iyer, Anand S., Kinney, Gregory L., Hanania, Nicola A., Lowe, Katherine E., Holm, Kristen E., Yohannes, Abebaw M., Shinozaki, Gen, and Fiedorowicz, Jess G.
- Published
- 2023
- Full Text
- View/download PDF
46. Lack of racial and ethnic disparities in mortality in minority patients hospitalised with COVID-19 in a mid-Atlantic healthcare system
- Author
-
Galiatsatos, Panagis, primary, Garibaldi, Brian, additional, Yao, Dapeng, additional, Xu, Yanxun, additional, Perin, Jamie, additional, Shahu, Andi, additional, Jackson, John W, additional, Piggott, Damani, additional, Falade-Nwulia, Oluwaseun, additional, Shubella, Jocelyn, additional, Michtalik, Henry, additional, Belcher, Harolyn M E, additional, Hansel, Nadia N, additional, and Golden, Sherita, additional
- Published
- 2024
- Full Text
- View/download PDF
47. Air Pollution Exposure and Interstitial Lung Features in SPIROMICS Participants with COPD
- Author
-
Baddour, Nicolas A., primary, Paulin, Laura M, additional, Gassett, Amanda J., additional, Woo, Han, additional, Hoffman, Eric A., additional, Newell, John D, additional, Woodruff, Prescott G., additional, Pirozzi, Cheryl S., additional, Barjaktarevic, Igor, additional, Barr, R Graham, additional, O'Neal, Wanda, additional, Han, MeiLan K., additional, Martinez, Fernando J., additional, Peters, Stephen P., additional, Hastie, Annette T., additional, Hansel, Nadia N, additional, Ortega, Victor E., additional, Kaufman, Joel D., additional, and Sack, Coralynn S., additional
- Published
- 2024
- Full Text
- View/download PDF
48. A Genetic Risk Score Associated with Chronic Obstructive Pulmonary Disease Susceptibility and Lung Structure on Computed Tomography
- Author
-
Oelsner, Elizabeth C, Ortega, Victor E, Smith, Benjamin M, Nguyen, Jennifer N, Manichaikul, Ani W, Hoffman, Eric A, Guo, Xiuqing, Taylor, Kent D, Woodruff, Prescott G, Couper, David J, Hansel, Nadia N, Martinez, Fernando J, Paine, Robert, Han, Meilan K, Cooper, Christopher, Dransfield, Mark T, Criner, Gerard, Krishnan, Jerry A, Bowler, Russell, Bleecker, Eugene R, Peters, Stephen, Rich, Stephen S, Meyers, Deborah A, Rotter, Jerome I, and Barr, R Graham
- Subjects
Lung Cancer ,Lung ,Tobacco Smoke and Health ,Genetics ,Clinical Research ,Chronic Obstructive Pulmonary Disease ,Tobacco ,Prevention ,Biomedical Imaging ,Cancer ,2.1 Biological and endogenous factors ,Aetiology ,Respiratory ,Good Health and Well Being ,Aged ,Female ,Genetic Predisposition to Disease ,Humans ,Male ,Middle Aged ,Pulmonary Disease ,Chronic Obstructive ,Risk Assessment ,Tomography ,X-Ray Computed ,United States ,spirometry ,emphysema ,airway remodeling ,Medical and Health Sciences ,Respiratory System - Abstract
Rationale: Chronic obstructive pulmonary disease (COPD) has been associated with numerous genetic variants, yet the extent to which its genetic risk is mediated by variation in lung structure remains unknown.Objectives: To characterize associations between a genetic risk score (GRS) associated with COPD susceptibility and lung structure on computed tomography (CT).Methods: We analyzed data from MESA Lung (Multi-Ethnic Study of Atherosclerosis Lung Study), a U.S. general population-based cohort, and SPIROMICS (Subpopulations and Intermediate Outcome Measures in COPD Study). A weighted GRS was calculated from 83 SNPs that were previously associated with lung function. Lung density, spatially matched airway dimensions, and airway counts were assessed on full-lung CT. Generalized linear models were adjusted for age, age squared, sex, height, principal components of genetic ancestry, smoking status, pack-years, CT model, milliamperes, and total lung volume.Measurements and Main Results: MESA Lung and SPIROMICS contributed 2,517 and 2,339 participants, respectively. Higher GRS was associated with lower lung function and increased COPD risk, as well as lower lung density, smaller airway lumens, and fewer small airways, without effect modification by smoking. Adjustment for CT lung structure, particularly small airway measures, attenuated associations between the GRS and FEV1/FVC by 100% and 60% in MESA and SPIROMICS, respectively. Lung structure (P 0.10), improved discrimination of moderate-to-severe COPD cases relative to clinical factors alone.Conclusions: A GRS associated with COPD susceptibility was associated with CT lung structure. Lung structure may be an important mediator of heritability and determinant of personalized COPD risk.
- Published
- 2019
49. Author Correction: Association study in African-admixed populations across the Americas recapitulates asthma risk loci in non-African populations.
- Author
-
Daya, Michelle, Rafaels, Nicholas, Brunetti, Tonya M, Chavan, Sameer, Levin, Albert M, Shetty, Aniket, Gignoux, Christopher R, Boorgula, Meher Preethi, Wojcik, Genevieve, Campbell, Monica, Vergara, Candelaria, Torgerson, Dara G, Ortega, Victor E, Doumatey, Ayo, Johnston, Henry Richard, Acevedo, Nathalie, Araujo, Maria Ilma, Avila, Pedro C, Belbin, Gillian, Bleecker, Eugene, Bustamante, Carlos, Caraballo, Luis, Cruz, Alvaro, Dunston, Georgia M, Eng, Celeste, Faruque, Mezbah U, Ferguson, Trevor S, Figueiredo, Camila, Ford, Jean G, Gan, Weiniu, Gourraud, Pierre-Antoine, Hansel, Nadia N, Hernandez, Ryan D, Herrera-Paz, Edwin Francisco, Jiménez, Silvia, Kenny, Eimear E, Knight-Madden, Jennifer, Kumar, Rajesh, Lange, Leslie A, Lange, Ethan M, Lizee, Antoine, Maul, Pissamai, Maul, Trevor, Mayorga, Alvaro, Meyers, Deborah, Nicolae, Dan L, O'Connor, Timothy D, Oliveira, Ricardo Riccio, Olopade, Christopher O, Olopade, Olufunmilayo, Qin, Zhaohui S, Rotimi, Charles, Vince, Nicolas, Watson, Harold, Wilks, Rainford J, Wilson, James G, Salzberg, Steven, Ober, Carole, Burchard, Esteban G, Williams, L Keoki, Beaty, Terri H, Taub, Margaret A, Ruczinski, Ingo, Mathias, Rasika A, Barnes, Kathleen C, and CAAPA
- Subjects
CAAPA - Abstract
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
- Published
- 2019
50. Aspirin Use and Respiratory Morbidity in COPD: A Propensity Score-Matched Analysis in Subpopulations and Intermediate Outcome Measures in COPD Study.
- Author
-
Fawzy, Ashraf, Putcha, Nirupama, Aaron, Carrie P, Bowler, Russell P, Comellas, Alejandro P, Cooper, Christopher B, Dransfield, Mark T, Han, MeiLan K, Hoffman, Eric A, Kanner, Richard E, Krishnan, Jerry A, Labaki, Wassim W, Paine, Robert, Paulin, Laura M, Peters, Stephen P, Wise, Robert, Barr, R Graham, Hansel, Nadia N, and SPIROMICS Investigators
- Subjects
SPIROMICS Investigators ,Humans ,Pulmonary Disease ,Chronic Obstructive ,Aspirin ,Platelet Aggregation Inhibitors ,Glucocorticoids ,Anti-Bacterial Agents ,Respiratory Function Tests ,Severity of Illness Index ,Prospective Studies ,Middle Aged ,United States ,Female ,Male ,Symptom Assessment ,Symptom Flare Up ,Correlation of Data ,COPD ,acute exacerbation of chronic bronchitis ,antiplatelet drugs ,dyspnea ,quality of life ,Lung ,Clinical Research ,Rehabilitation ,Chronic Obstructive Pulmonary Disease ,Respiratory ,Good Health and Well Being ,Clinical Sciences ,Respiratory System - Abstract
BackgroundAspirin use in COPD has been associated with reduced all-cause mortality in meta-regression analysis with few equivocal studies. However, the effect of aspirin on COPD morbidity is unknown.MethodsSelf-reported daily aspirin use was obtained at baseline from SPIROMICS participants with COPD (FEV1/FVC < 70%). Acute exacerbations of COPD (AECOPD) were prospectively ascertained through quarterly structured telephone questionnaires up to 3 years and categorized as moderate (symptoms treated with antibiotics or oral corticosteroids) or severe (requiring ED visit or hospitalization). Aspirin users were matched one-to-one with nonusers, based on propensity score. The association of aspirin use with total, moderate, and severe AECOPD was investigated using zero-inflated negative binomial models. Linear or logistic regression was used to investigate the association with baseline respiratory symptoms, quality of life, and exercise tolerance.ResultsAmong 1,698 participants, 45% reported daily aspirin use at baseline. Propensity score matching resulted in 503 participant pairs. Aspirin users had a lower incidence rate of total AECOPD (adjusted incidence rate ratio [IRR], 0.78; 95% CI, 0.65-0.94), with similar effect for moderate but not severe AECOPD (IRR, 0.86; 95% CI, 0.63-1.18). Aspirin use was associated with lower total St. George's Respiratory Questionnaire score (β, -2.2; 95% CI, -4.1 to -0.4), reduced odds of moderate-severe dyspnea (modified Medical Research Council questionnaire score ≥ 2; adjusted odds ratio, 0.69; 95% CI, 0.51-0.93), and COPD Assessment Test score (β, -1.1; 95% CI, -1.9 to -0.2) but not 6-min walk distance (β, 0.7 m; 95% CI, -14.3 to 15.6).ConclusionsDaily aspirin use is associated with reduced rate of COPD exacerbations, less dyspnea, and better quality of life. Randomized clinical trials of aspirin use in COPD are warranted to account for unmeasured and residual confounding.Trial registryClinicalTrials.gov; No.: NCT01969344; URL: www.clinicaltrials.gov.
- Published
- 2019
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.